TW200916098A - Agent for lowering uric acid level - Google Patents
Agent for lowering uric acid level Download PDFInfo
- Publication number
- TW200916098A TW200916098A TW097122309A TW97122309A TW200916098A TW 200916098 A TW200916098 A TW 200916098A TW 097122309 A TW097122309 A TW 097122309A TW 97122309 A TW97122309 A TW 97122309A TW 200916098 A TW200916098 A TW 200916098A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- substituted
- linear
- branched
- unsubstituted
- Prior art date
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229940116269 uric acid Drugs 0.000 title claims abstract description 41
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 22
- 125000003118 aryl group Chemical group 0.000 claims abstract description 53
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 306
- 229910052799 carbon Inorganic materials 0.000 claims description 277
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 213
- 125000000217 alkyl group Chemical group 0.000 claims description 160
- 125000001424 substituent group Chemical group 0.000 claims description 126
- 125000005843 halogen group Chemical group 0.000 claims description 125
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 118
- 229910052757 nitrogen Inorganic materials 0.000 claims description 113
- 125000003545 alkoxy group Chemical group 0.000 claims description 98
- 150000001721 carbon Chemical class 0.000 claims description 94
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 72
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 68
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 63
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 61
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 60
- 125000005842 heteroatom Chemical group 0.000 claims description 59
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 59
- 201000005569 Gout Diseases 0.000 claims description 57
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 54
- 125000004434 sulfur atom Chemical group 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 47
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 47
- 229910052717 sulfur Inorganic materials 0.000 claims description 46
- 125000004951 trihalomethoxy group Chemical group 0.000 claims description 46
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 44
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 41
- -1 5-oxo-1,2,4-thiadiazolyl Chemical group 0.000 claims description 39
- 125000004122 cyclic group Chemical group 0.000 claims description 39
- 125000003277 amino group Chemical group 0.000 claims description 31
- 125000004414 alkyl thio group Chemical group 0.000 claims description 30
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 29
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 28
- 201000001431 Hyperuricemia Diseases 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 208000017169 kidney disease Diseases 0.000 claims description 26
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 25
- 229940124597 therapeutic agent Drugs 0.000 claims description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 22
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 21
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 19
- 230000000069 prophylactic effect Effects 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000001624 naphthyl group Chemical group 0.000 claims description 13
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
- 208000019622 heart disease Diseases 0.000 claims description 11
- 210000003734 kidney Anatomy 0.000 claims description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 10
- 206010003246 arthritis Diseases 0.000 claims description 10
- 201000006370 kidney failure Diseases 0.000 claims description 10
- 206010054107 Nodule Diseases 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 208000000913 Kidney Calculi Diseases 0.000 claims description 8
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 8
- 208000009911 Urinary Calculi Diseases 0.000 claims description 8
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 8
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 8
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 7
- XBBXVAQUELRTQO-UHFFFAOYSA-N [Bi].N1C(=O)NC=2NC(=O)NC2C1=O Chemical compound [Bi].N1C(=O)NC=2NC(=O)NC2C1=O XBBXVAQUELRTQO-UHFFFAOYSA-N 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- 230000003449 preventive effect Effects 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 201000008383 nephritis Diseases 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 230000002618 waking effect Effects 0.000 claims description 5
- ASUMVAPLXCRBMA-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(2,3-dihydro-1,4-benzoxazin-4-yl)methanone Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2OCC1 ASUMVAPLXCRBMA-UHFFFAOYSA-N 0.000 claims description 4
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 4
- 208000006029 Cardiomegaly Diseases 0.000 claims description 4
- 229940083914 URAT1 inhibitor Drugs 0.000 claims description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000006371 dihalo methyl group Chemical group 0.000 claims description 4
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 150000002429 hydrazines Chemical class 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 229910052707 ruthenium Inorganic materials 0.000 claims description 2
- RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical group SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 claims description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000003544 oxime group Chemical group 0.000 claims 5
- 150000003536 tetrazoles Chemical class 0.000 claims 4
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
- 239000004952 Polyamide Substances 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims 2
- 229920002647 polyamide Polymers 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims 1
- CXUJMACGOZZVIL-UHFFFAOYSA-N CNN.C1=CC=CC=2C3=CC=CC=C3CC12 Chemical compound CNN.C1=CC=CC=2C3=CC=CC=C3CC12 CXUJMACGOZZVIL-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 150000001924 cycloalkanes Chemical class 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 1
- 150000007857 hydrazones Chemical class 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000542 sulfonic acid group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 38
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- 150000001875 compounds Chemical class 0.000 description 28
- 229940088598 enzyme Drugs 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 210000005003 heart tissue Anatomy 0.000 description 5
- 102000056457 human SLC22A12 Human genes 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 101100048829 Arabidopsis thaliana URT1 gene Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010038519 Renal rickets Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 201000006409 renal osteodystrophy Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ODVMSANIQQEWOU-UHFFFAOYSA-N CN(CCO)C.NN Chemical compound CN(CCO)C.NN ODVMSANIQQEWOU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101710108470 Hyalin Proteins 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical group CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000012754 barrier agent Substances 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- QDHFHIQKOVNCNC-UHFFFAOYSA-N butane-1-sulfonic acid Chemical compound CCCCS(O)(=O)=O QDHFHIQKOVNCNC-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- VAWSWDPVUFTPQO-UHFFFAOYSA-N calcium strontium Chemical compound [Ca].[Sr] VAWSWDPVUFTPQO-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000010436 fluorite Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 description 1
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940023877 zeatin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
200916098 九、發明說明 【發明所屬之技術領域】 本發明係有關降低尿酸値用劑。具體而言係有關含有 式(I)所示之含氮芳香環衍生物或其鹽爲有效成分之降 低尿酸値用劑。 【先前技術】 尿酸係於體內依存pH作成尿酸或其鹽存在之,主要 由腎臟被排泄。藉由高尿酸血症,其血中尿酸値超出溶解 度後’尿酸鈉結晶將沉澱於關節等,而產生痛風。該症狀 包含痛風關節炎(痛風發作)、痛風結節' 尿路結石之腎 障礙等代表之,而痛風患者中其他亦複合性合倂肥胖、高 血壓、高脂血症、耐糖能異常等,此等合倂症之集成性被 認爲關係著痛風的預後(非專利文獻1 )。未調整血清尿 酸値放任後’將漸次頻頻引起痛風關節炎,轉形成慢性痛 風關節炎,導致出現痛風結節。且,長時間持續出現高尿 酸血症則出現腎結石、尿路結石、腎髓質之間質性腎炎產 生’倂發所謂痛風腎之病態。更有自古既知的高度血清尿 酸値將提昇缺血性心疾病的危險性,高尿酸血症顯示心血 管疾病、腦血管疾病之危險因子。 血中之尿酸係於腎絲球體被過濾,大半於近位尿細管 被再吸收’故通常僅些微於尿中被排泄。近年證明UR AT i 係於腎臟的近位尿細管中擔任尿酸再吸收之中心輸送體, 阻擾 URAT1之殘苯磺二丙胺(probenecid )或 200916098 benzbromarone被揭示爲適用於痛風等之治療藥或預防藥 (非專利文獻2 )。 另外’本發明所使用之化合物作爲具有阻礙酵素製劑 活性之化合物群被揭示於專利文獻1〜4。 酵素製劑(chymase)係存在於mast cell顆粒中之1 種中性蛋白酶,深切的關係著mast cell相關之各種生體 反應。如:尚血壓蛋白寧(Angiotensin, Ang) I轉換成 Ang II之轉換作用,原複合金屬蛋白酶(promatrix metalloprotease )之活性化、由 Endothelin 轉爲 Endothelin ( 1〜31 )之轉換作用,轉換成長因子召( Transforming growth factor-石,TGF-;(S )之活性化、介白 質-1 - /3 ( Interl eukin-1 β , IL-1 β )、介白質-18 (200916098 IX. INSTRUCTIONS OF THE INVENTION [Technical Field to Be Invented by the Invention] The present invention relates to an agent for reducing uric acid bismuth. Specifically, it relates to a composition for reducing uric acid bismuth containing the nitrogen-containing aromatic ring derivative represented by the formula (I) or a salt thereof as an active ingredient. [Prior Art] Uric acid is present in the body depending on the pH to form uric acid or a salt thereof, and is mainly excreted by the kidney. With hyperuricemia, the uric acid strontium in the blood exceeds the solubility, and sodium urate crystals will precipitate in the joints and the like, and gout will occur. The symptoms include gout arthritis (gout attack), gout nodules, renal disorders of urinary calculi, and other gout patients with complex obesity, hypertension, hyperlipidemia, and glucose tolerance. The integration of the complication is considered to be related to the prognosis of gout (Non-Patent Document 1). Unadjusted serum uric acid sputum will gradually cause gout arthritis, which will gradually form chronic gout arthritis, leading to gout nodules. Moreover, if hyperuricemia persists for a long time, kidney stones, urinary calculi, and renal medulla interstitial nephritis produce a disease called sore gout. More highly known serum uric acid sputum will increase the risk of ischemic heart disease, and hyperuricemia shows risk factors for cardiovascular disease and cerebrovascular disease. The uric acid in the blood is filtered by the renal spheroid, and most of the urinary tract is reabsorbed. Therefore, it is usually only slightly excreted in the urine. In recent years, UR AT i has been shown to act as a central transporter of uric acid reabsorption in the proximal urinary tract of the kidney. The probenecid or the 200916098 benzbromarone that interferes with URAT1 is disclosed as a therapeutic or preventive agent for gout. Medicine (Non-Patent Document 2). Further, the compound used in the present invention is disclosed in Patent Documents 1 to 4 as a compound having a compound which inhibits the activity of an enzyme preparation. The chymase is a neutral protease present in the mast cell granules, which is closely related to various biological reactions related to the mast cell. For example, the conversion of Angiotensin (Ang) I to Ang II, the activation of promatrix metalloprotease, the conversion from Endothelin to Endothelin (1~31), and the conversion of growth factors (Transformation growth factor-stone, TGF-; (S) activation, interleukin-1 - /3 (Interl eukin-1 β, IL-1 β), interleukin-18 (
Interleukin-18,IL-18)之活性化、纖維網蛋白、玻璃網蛋 白、I型膠原之製程之外,實物(Substance P)、活化血 管腸內多胜肽(Vasoactive intestinal polypeptide, VIP) 、抑制組織因子經路(Tissue factor pathway inhibitor) 之活性化等各種作用被揭示之。 由以上,被認爲具有阻礙酵素製劑活性之化合物,對 於心臟病,如:心臟肥大、心臟衰竭、或心肌梗塞;腎臟 病,如:糖尿病性腎症、腎衰竭、腎病、或腎炎;過敏性 病患,如:Atopy性皮膚炎等,可作成有效之預防劑及/或 治療劑。 [非專利文獻1 ]有關疋田美穗 高尿酸血症中生活 習慣病、糖代謝異常之關連的硏究 痛風與核酸代謝 -6 - 200916098 2000; 24: 139-151 [非專利文獻2]蛋白質核酸 酵素、Vol. 48,No. 1 (2003) [專利文獻1]國際公開第200 1/5329 1號手冊 [專利文獻2]國際公開第2000/03 997號手冊 [專利文獻3]國際公開第2007/06 8 62 1號手冊 [專利文獻4]國際公開第2008/045 68 8號手冊 【發明內容】 本發明之目的係爲提供一種新穎的UR AT 1阻礙劑或 降低尿酸値用劑。本發明又爲提供一種有效治療、預防其 有關新穎的痛風 '高尿酸血症、痛風關節炎、痛風結節、 尿路結石、腎結石、腎障礙、痛風腎、心血管疾病、或腦 血管疾病等尿酸相關之疾病的良好的降低尿酸値用劑爲其 目的。本發明更提供一種伴隨痛風或高尿酸血症之心臟病 的預防劑或治療劑爲其目的。 亦即,本發明係含有式(I)所示之含氮芳香環衍生 物或其鹽爲有效成分之u R A T 1阻礙劑;降低尿酸値用劑 :痛風、高尿酸血症、或尿酸相關之疾病(如:痛風關節 炎、痛風結節、尿路結石、腎結石、腎障礙、痛風腎、心 血管疾病、或腦血管疾病等)之預防劑或治療劑;伴隨痛 風或高尿酸血症之心臟病(如:心臟肥大、心臟衰竭、或 ;匕、肌梗垂寺)之預防劑或治療劑,伴隨痛風或高尿酸血症 之腎臓病(如:糖尿病性腎症、腎衰竭、腎病、或腎炎等 200916098 )之預防劑或治療劑。 【化1】Interleunation-18, IL-18) activation, fibrin, hyalin, and type I collagen, Substance P, Vasoactive intestinal polypeptide (VIP), inhibition Various effects such as activation of tissue factor pathway inhibitors are revealed. From the above, it is considered to have a compound which hinders the activity of an enzyme preparation, for heart disease such as cardiac hypertrophy, heart failure, or myocardial infarction; kidney disease such as diabetic nephropathy, renal failure, kidney disease, or nephritis; allergic Patients, such as: Atopy dermatitis, can be used as effective prophylactic and / or therapeutic agents. [Non-Patent Document 1] Related to Gout and Glucose Metabolism Related to Lifestyle-related Diseases and Abnormal Glucose Metabolism in Usimi Mihopurine-6 - 200916098 2000; 24: 139-151 [Non-Patent Document 2] Protein Nucleic Acid Enzyme Vol. 48, No. 1 (2003) [Patent Document 1] International Publication No. 2001 1/5329 No. 1 Manual [Patent Document 2] International Publication No. 2000/03 997 Manual [Patent Document 3] International Publication No. 2007/ 06 8 62 No. 1 Manual [Patent Document 4] International Publication No. 2008/045 68 No. 8 [Invention] The object of the present invention is to provide a novel UR AT 1 inhibitor or a urate-reducing agent. The invention further provides an effective treatment and prevention of novel gout 'hyperuricemia, gout arthritis, gout nodules, urinary calculi, kidney stones, kidney disorders, gout kidney, cardiovascular diseases, or cerebrovascular diseases, etc. A good uric acid-lowering agent for uric acid-related diseases for its purpose. The present invention further provides a prophylactic or therapeutic agent for heart disease accompanied by gout or hyperuricemia. That is, the present invention is a u RAT 1 inhibitor containing the nitrogen-containing aromatic ring derivative represented by the formula (I) or a salt thereof as an active ingredient; and a urate-reducing agent: gout, hyperuricemia, or uric acid-related a preventive or therapeutic agent for diseases such as gout arthritis, gout nodules, urinary calculi, kidney stones, kidney disorders, gout kidneys, cardiovascular diseases, or cerebrovascular diseases; the heart with gout or hyperuricemia A prophylactic or therapeutic agent for a disease (eg, cardiac hypertrophy, heart failure, or sputum, muscle stagnation temple), renal rickets associated with gout or hyperuricemia (eg, diabetic nephropathy, renal failure, kidney disease, or A preventive or therapeutic agent for nephritis and the like 200916098). 【化1】
[式(I)中’ R1及R2代表同時或各自獨立之氫原子、鹵素眉 三鹵素甲基、氰基、羥基、碳數1〜4之烷基或碳數 之院氧基、或R及R2爲連接之- 〇_CH2-0-、-〇-CH2 Ο-或R2爲連接時,其碳數亦石 個或多數個碳數1〜4之烷基所取代); A爲單鍵’代表取代或無取代之碳數1〜6之搶 支鏈狀、或環狀之伸烷基、取代或無取代之碳數6〜 伸芳基、或取代或無取代之於環上具有1個以上選自 子、氮原子及硫原子所成群之雜原子之碳數4〜1〇之 芳基{作爲A之取代基者如:鹵素原子、羥基、硝基 基、直鏈或支鏈狀之碳數1〜6之烷基、直鏈或支齒 碳數1〜6之烷氧基(作爲取代基 > 鄰接之2個烷_ 可形成縮醒鍵)、直鏈或支鏈狀之碳數1〜6之烷标 直鏈或支鏈狀之碳數1〜6之烷基磺醯基、直鏈或3 之碳數1〜ό之醯基、直鏈或支鏈狀之碳數1〜6之® 基'二鹵素甲基、三鹵素甲氧基、苯基'氧基、或被 i子、 1〜4 -ch2- 丁被1 :鏈、 1 1之 i氧原 :雜伸 j、氰 丨狀之 4基亦 :基、 :鏈狀 丨基胺 1個 200916098 以上之鹵素原子所取代亦可之苯氧基。此等亦可於環或伸 垸基之任意位置以1個或多數個各自獨立取代 E 代表- C〇〇R3、. s 〇 3 R3 ' -CONHR3、- S 02NHR3 ' 四 哩基、5-氧基-hi噁二唑基、或5-氧基-二唑基 (R3代表氫原子或直鏈或支鏈狀之碳數1〜6之烷基); G代表取代或無取代之碳數1〜6之直鏈或支鏈狀之 伸院基’途中亦可含有!個或多數個〇、S、s〇2、NR3。 (R爲相同於上述R3之定義。G之取代基如:鹵素原子 、羥基、硝基、氰基、直鏈或支鏈狀之碳數1〜6之院基 、直鏈或支鏈狀之碳數1〜ό之烷氧基(作爲取代基,鄰 fe之2個烷氧基亦可形成縮醛醚)、三鹵素甲基、三鹵素 甲氧基、苯基、或氧基}; Μ代表單鍵或_s(〇)m_,m代表〇〜2之整數; 】當m爲0且A爲取代或無取代之碳數〗〜6之直鏈 、支鏈狀或環狀之伸烷基時’代表取代或無取代之碳數3 6之直鏈、環狀或支鏈狀之垸基,取代或無取代之碳數 7〜11之芳基、或取代或無取代之於環上具有丨個以上選 自氧原子、氮原子、及硫原子所成群之雜原子之碳數4〜 1 0之雜方基。 J當m爲〇且八爲取代或無取代之碳數6〜11之伸芳 基、或取代或無取代之於環上具有丨個以上選自氧原子' 氮原子及硫原子所成群之雜原子之碳數4〜1〇之雜伸芳 時,代表取代或無取什,陡齡,r ^ _乂代之5灰數1〜6之直鏈、環狀或支鏈 狀之烷基、取代或無取代之碳數卜} i之芳基伴" 4取代或 200916098 無取代之環上具有丨個以上選自氧原子、氮原子及硫原子 所成群之雜原子之碳數4〜10之雜芳基。 J爲’當Μ爲單鍵、m爲〇且a爲單鍵、或m爲1或 2時’代表取代或無取代之碳數1〜6之直鏈、環狀或支鏈 狀之院基、取代或無取代之碳數6〜1 1之芳基、或取代或 無取代之環上具有1個以上選自氧原子、氮原子及硫原子 所成群之雜原子之碳數4〜1〇之雜芳基。 {作爲J之取代基者如:鹵素原子、經基、硝基、氰 基、直鏈或支鏈狀之碳數1〜6之烷基、直鏈或支鏈狀之 碳數1〜6之烷氧基(作爲取代基,鄰接之2個烷氧基亦 可形成縮醛鍵)、直鏈或支鏈狀之碳數1〜6之烷硫基、 直鏈或支鏈狀之碳數1〜6之烷基磺醯基、直鏈或支鏈狀 之碳數1〜6之醯基、直鏈或支鏈狀之碳數1〜6之醯基胺 基、取代或無取代之醯替苯胺基、三鹵素甲基、三鹵素甲 氧基、苯基、氧基、COOR3基(R3爲相同於上述之定義 )、或亦可被1個以上之鹵素原子所取代之苯氧基。此等 亦可於環或烷基之任意位置以!個或多數個各自取代}; X代表-CH =或氮原子; γ代表-CB =或氮原子; B係以-B 1 - B2 - B3示之; B1代表單鍵或直鏈或支鏈狀之碳數1〜3之伸烷基; B2代表單鍵、-CO-或-NR3-。(其中,R3爲相同於上 述R3之定義): B3代表氫原子、鹵素原子、硝基、氰基、羥基、磺醯 -10- 200916098 基、取代或無取代之直鏈或支鏈狀之碳數1〜6之烷基、 取代或無取代之直鏈或支鏈狀之碳數1〜6之烷氧基、取 代或無取代之碳數6〜11之芳基、取代或無取代之環上具 有1個以上選自氧原子、氮原子及硫原子所成群之雜原子 之碳數4〜1 〇之雜芳基、取代或無取代之胺基、取代或無 取代之羧基、取代或無取代之直鏈或支鏈狀之碳數1〜6 之烷基磺醯基、取代或無取代之苯基磺醯基、取代或無取 代之直鏈或支鏈狀之碳數1〜6之胺基烷基磺醯基、取代 或無取代之直鏈或支鏈狀之碳數1〜8之醯基、取代或無 取代之直鏈或支鏈狀之碳數1〜6之烷氧基羰基、取代或 無取代之苯基羯基、碳數1〜6之直鏈或支鏈狀之垸硫基 、三鹵素甲基或三鹵素甲氧基{作爲B3之取代基者如:鹵 素原子、羥基、胺基、羧基、硝基、氰基、直鏈或支鏈狀 之碳數1〜6之烷基、直鏈或支鏈狀之碳數1〜6之院氧基 (作爲取代基’鄰接之2個院氧基亦可形成縮醒鍵)、三 鹵素甲基、或三鹵素甲氧基。此等亦可於任意之位置以1 個或多數個各自獨立取代}; Z代表碳原子或氮原子; Q代表碳原子或氮原子。]。] 又’本發明爲4-(1-( (4 -甲基-1-氧基苯並噻吩-3_ 基)甲基)苯並咪唑-2-硫代)丁酸或其鹽。 本發明藉由投予藥劑後,可阻礙UR AT 1,且可降低_ 酸値’可作爲降低尿酸値用劑之使用。又,本發明之藥劑 可適用於痛風、高尿酸血症、痛風關節炎、痛風結節、尿 -11 - 200916098 路結石、腎結石、腎障礙、痛風腎、心血管疾病、或腦血 管疾病等之尿酸相關疾病的預防劑或治療劑。本發明有效 成分之化合物或其鹽,進一步具有阻礙酵素製劑活性,因 此亦可適用於伴隨痛風或高尿酸血症之心臟病或腎臟病之 預防劑或治療劑。 【實施方式】 [發明實施之最佳形態] 作爲本發明藥劑所使用之含氮芳香環衍生物或其鹽之 含氮芳香環衍生物係以式(I )所示之化合物。[In the formula (I), 'R1 and R2 represent a hydrogen atom at the same time or independently, a halogen eyebrow trihalomethyl group, a cyano group, a hydroxyl group, an alkyl group having a carbon number of 1 to 4 or a carbon number, or R and R2 is a combination of - 〇_CH2-0-, -〇-CH2 Ο- or R2 is a ring, the carbon number is also substituted by a stone or a plurality of alkyl groups having 1 to 4 carbon atoms; A is a single bond' a substituted or unsubstituted carbon number of 1 to 6 or a cyclic alkyl group, a substituted or unsubstituted carbon number 6 to an aryl group, or a substituted or unsubstituted one having 1 ring The aryl group having a carbon number of 4 to 1 Å selected from the group consisting of a hetero atom and a nitrogen atom and a sulfur atom. {As a substituent of A, such as a halogen atom, a hydroxyl group, a nitro group, a linear chain or a branched chain. An alkyl group having 1 to 6 carbon atoms, a linear or branched alkoxy group having 1 to 6 carbon atoms (as a substituent > 2 adjacent alkane _ can form a awake bond), a linear or branched chain Alkyl group having a carbon number of 1 to 6 or a linear or branched alkyl group having 1 to 6 carbon atoms, a straight chain or a carbon number of 1 to 3, a linear or branched carbon number 1~6® base 'dihalomethyl, trihalomethoxy, phenyl' oxygen , or by i, 1~4 -ch2-butyl is 1 : chain, 1 1 i oxygen: heterozygous j, cyanide-like 4 group also: base, : chain decylamine 1 200916098 A phenoxy group which may be substituted by a halogen atom. These may also be substituted for each of the ring or the thiol group by one or more of them independently - C 〇〇 R3, . s 〇 3 R3 ' -CONHR3, - S 02NHR3 'tetradecyl, 5-oxo a base-hi oxadiazolyl or a 5-oxy-diazolyl group (R3 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms); G represents a substituted or unsubstituted carbon number of 1 ~6 straight or branched chain extension base can also be included on the way! Or a majority of 〇, S, s〇 2, NR3. (R is the same as defined above for R3. The substituent of G is a halogen atom, a hydroxyl group, a nitro group, a cyano group, a linear or branched carbon number of 1 to 6 or a linear or branched chain. Alkoxy group having a carbon number of 1 to fluorene (as a substituent, two alkoxy groups of the same may form an acetal ether), a trihalomethyl group, a trihalomethoxy group, a phenyl group, or an oxy}; Represents a single bond or _s(〇)m_, m represents an integer of 〇~2; 】 a linear, branched or cyclic alkylene group when m is 0 and A is a substituted or unsubstituted carbon number of 〜6 The base group ' represents a substituted or unsubstituted carbonic acid number of 6 6 straight, cyclic or branched fluorenyl groups, substituted or unsubstituted aryl groups having 7 to 11 carbon atoms, or substituted or unsubstituted on the ring a heterocyclic group having from 4 to 10 carbon atoms of a hetero atom selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom. J when m is 〇 and eight is a substituted or unsubstituted carbon number 6~ An extended aryl group of 11 or a substituted or unsubstituted substituent having a carbon number of 4 to 1 Å selected from a hetero atom of a group selected from the group consisting of an oxygen atom and a nitrogen atom Or no, steep, r ^ _ Deuterated 5 ash number 1 to 6 linear, cyclic or branched alkyl, substituted or unsubstituted carbon number} i aryl group " 4 substitution or 200916098 unsubstituted ring with 丨More than one heteroaryl group having 4 to 10 carbon atoms selected from the group consisting of oxygen atoms, nitrogen atoms and sulfur atoms. J is 'when Μ is a single bond, m is 〇 and a is a single bond, or m is 1 or 2'' represents a substituted or unsubstituted, straight-chain, cyclic or branched, aryl group having a carbon number of from 6 to 1, substituted or unsubstituted, or substituted or unsubstituted. The ring has one or more heteroaryl groups having a carbon number of 4 to 1 Å selected from a hetero atom of a group consisting of an oxygen atom, a nitrogen atom and a sulfur atom. {As a substituent of J, a halogen atom, a thiol group, a nitro group, a cyano group, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkoxy group having 1 to 6 carbon atoms (as a substituent, 2 alkoxy groups adjacent thereto) It may also form an acetal bond, a linear or branched alkylthio group having 1 to 6 carbon atoms, a linear or branched alkylsulfonyl group having 1 to 6 carbon atoms, a linear or branched chain. a thiol, linear or branched chain having a carbon number of 1 to 6 a fluorenylamino group of 1 to 6, a substituted or unsubstituted anthranilyl group, a trihalomethyl group, a trihalomethoxy group, a phenyl group, an oxy group, a COOR3 group (R3 is the same as defined above), or a phenoxy group which may be substituted by one or more halogen atoms. These may also be substituted at each position of a ring or an alkyl group by one or a plurality of each;} X represents -CH= or a nitrogen atom; γ represents - CB = or nitrogen atom; B is represented by -B 1 - B2 - B3; B1 represents a single bond or a linear or branched alkyl group having 1 to 3 carbon atoms; B2 represents a single bond, -CO- or -NR3-. (wherein R3 is the same as defined in the above R3): B3 represents a hydrogen atom, a halogen atom, a nitro group, a cyano group, a hydroxyl group, a sulfonium-10-10, and a substituted or unsubstituted straight chain or branch. a chain-like alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted linear or branched alkoxy group having 1 to 6 carbon atoms, a substituted or unsubstituted aryl group having 6 to 11 carbon atoms, a substitution or a heteroaryl group having one or more carbon atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom, having 4 to 1 Å, a substituted or unsubstituted amino group, a substituted or a non-substituted ring a carboxy, substituted or unsubstituted linear or branched alkylsulfonyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenylsulfonyl group, a substituted or unsubstituted linear or branched chain. Aminoalkylsulfonyl group having 1 to 6 carbon atoms, substituted or unsubstituted linear or branched carbon group having 1 to 8 carbon atoms, substituted or unsubstituted linear or branched carbon number Alkoxycarbonyl group of 1 to 6, substituted or unsubstituted phenyl fluorenyl group, linear or branched thiol group having a carbon number of 1 to 6, trihalomethyl or trihalogen methoxy {as B3 The substituent is, for example, a halogen atom, a hydroxyl group, an amine group, a carboxyl group, a nitro group, a cyano group, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched carbon number of 1 to 6 The alkoxy group (which may also form a wake-up bond as two substituents adjacent to the substituent ') may be a trihalomethyl group or a trihalomethoxy group. These may also be independently substituted at one or a plurality of positions at any position}; Z represents a carbon atom or a nitrogen atom; and Q represents a carbon atom or a nitrogen atom. ]. Further, the present invention is 4-(1-((4-methyl-1-oxobenzothiophen-3-yl)methyl)benzimidazole-2-thio)butyric acid or a salt thereof. In the present invention, UR AT 1 can be inhibited by administration of a drug, and _ 値 値 can be reduced as a urate-reducing agent. Further, the agent of the present invention can be applied to gout, hyperuricemia, gout arthritis, gout nodules, urine-11 - 200916098 road stones, kidney stones, kidney disorders, gout kidneys, cardiovascular diseases, or cerebrovascular diseases, etc. A prophylactic or therapeutic agent for uric acid-related diseases. The compound of the active ingredient of the present invention or a salt thereof further inhibits the activity of the enzyme preparation, and thus can also be applied to a preventive or therapeutic agent for heart disease or kidney disease accompanied by gout or hyperuricemia. [Embodiment] The best mode for carrying out the invention The nitrogen-containing aromatic ring derivative used as the agent of the present invention or a salt-containing nitrogen-containing aromatic ring derivative thereof is a compound represented by the formula (I).
[式(I )中, R1及R2代表同時或各自獨立之氫原子、鹵素原子、 三鹵素甲基、氰基、羥基、直鏈或支鏈狀之碳數丨〜4之 烷基或直鏈或支鏈狀之碳數4之烷氧基、或…及R2 爲連接之-0-CH2-0-、 -0-CH2-CH2-0-^ -ch2-ch2-ch2- R1及R爲連接時,該碳數亦可被丨個或多數之直鏈或支 鏈狀之碳數1〜4之烷基取代); 1〜6之直鏈、 A爲單鍵,代表取代或無取代之碳數 -12- 200916098 支鏈狀、或環狀之伸烷基、取代或無取代之碳數6〜n之 伸芳基、或取代或無取代之於環上具有1個以上選自氧原 子、氮原子及硫原子所成群之雜原子之碳數4〜10之雜伸 芳基{作爲A之取代基者如:鹵素原子、羥基、硝基、氰 基、直鏈或支鏈狀之碳數1〜6之烷基、直鏈或支鏈狀之 碳數1〜6之烷氧基(作爲取代基,鄰接之2個烷氧基亦 可形成縮醒鍵)、直鏈或支鏈狀之碳數1〜6之烷硫基、 直鏈或支鏈狀之碳數1〜6之烷基磺醯基、直鏈或支鏈狀 之碳數1〜6之醯基、直鏈或支鏈狀之碳數1〜6之醯基胺 基、三鹵素甲基、三鹵素甲氧基、苯基、氧基、或以1個 以上之鹵素原子取代亦可之苯氧基。此等亦可於環或伸烷 基之任意位置以1個或多數個各自獨立取代 E 代表-COOR3、-S03R3、-CONHR3、-SO2NHR3、四 唑基、5 -氧基-1,2,4-噁二唑基或5 -氧基-1,2,4 -噻二唑基( R3代表氫原子或直鏈或支鏈狀之碳數1〜6之烷基); G代表取代或無取代之碳數1〜6之直鏈或支鏈狀之 伸烷基,途中亦可含有1個或多數個〇、S、S02、NR3。 {R3爲相同於上述V之定義。作爲G之取代基者如:鹵素 原子、經基、硝基、氨基、直鍵或支鍵狀之碳數1〜6之 烷基、直鏈或支鏈狀之碳數1〜6之烷氧基(作爲取代基 ,鄰接之2個烷氧基亦可形成縮醛醚)、三鹵素甲基、三 鹵素甲氧基、苯基、或氧基}; M代表單鍵或- S(0)m-,m代表〇〜2之整數; J當m爲0且A爲取代或無取代之碳數1〜6之直鏈 -13- 200916098 、環狀或支鏈狀之伸烷基時,代表取代或無取代之碳數3 〜6之直鏈、環狀或支鏈狀之烷基’取代或無取代之碳數 7〜11之芳基、或取代或無取代之於環上具有1個以上選 自氧原子、氮原子、及硫原子所成群之雜原子之碳數4〜 1 〇之雜芳基。 J代表當m爲〇且a代表取代或無取代之碳數6〜n 之伸芳基、或取代或無取代之於環上具有1個以上選自氧 原子、氮原子及硫原子所成群之雜原子之碳數4〜10之雜 伸芳基時’取代或無取代之碳數1〜6之直鏈、環狀或支 鏈狀之院基、取代或無取代之碳數6〜11之芳基、或取代 或無取代之環上具有丨個以上選自氧原子、氮原子及硫原 子所成群之雜原子之碳數4〜之雜芳基。 J當Μ爲單鍵、„1爲〇且a爲單鍵、或〇1爲1或2時 ’代表取代或無取代之碳數1〜6之直鏈、環狀或支鏈狀 之院基、取代或無取代之碳數6〜之芳基、或取代或無 取代之環上具有1個以上選自氧原子、氮原子及硫原子所 成群之雜原子之碳數4〜1〇之雜芳基。 {作爲J之取代基者如:鹵素原子、羥基、硝基、氰 基、直鏈或支鏈狀之碳數1〜6之烷基、直鏈或支鏈狀之 碳數1〜6之烷氧基(作爲取代基,鄰接之2個烷氧基亦 可形成縮醛鍵)、直鏈或支鏈狀之碳數!〜6之烷硫基、 直鍵或支鏈狀之碳數1〜6之烷基磺醯基、直鏈或支鏈狀 之碳數1〜6之醯基、直鏈或支鏈狀之碳數1〜6之醯基胺 基、取代或無取代之醯替苯胺基、三齒素甲基、三鹵素甲 -14- 200916098 氧基、苯基、氧基、COOR3基(R3爲相同於上述R3之定 義)、或以1個以上之鹵素原子取代亦可之苯氧基,此等 亦可於環或烷基之任意位置以1個或多數個各自獨立取代 }; X代表-CH =或氮原子; Y代表-CB =或氮原子; B係以-B 1 - B 2 - B 3示之; B 1代表單鍵或直鏈或支鏈狀之碳數1〜3之伸烷基; B2代表單鍵、-CO-或-NR3-(其中,R3爲相同於上述 之定義); B3代表氫原子、鹵素原子 '硝基、氰基、羥基、磺醯 基 '取代或無取代之直鏈或支鏈狀之碳數1〜6之烷基、 取代或無取代之直鏈或支鏈狀之碳數1〜6之烷氧基、取 代或無取代之碳數6〜11之芳基、取代或無取代之環上具 有1個以上選自氧原子、氮原子及硫原子所成群之雜原子 之碳數4〜10之雜芳基、取代或無取代之胺基、取代或無 取代之羧基、取代或無取代之直鏈或支鏈狀之碳數1〜6 之院基磺醯基、取代或無取代之苯基磺醯基、取代或無取 代'之直鏈或支鏈狀之碳數1〜6之胺基烷基磺醯基、取代 或無取代之直鏈或支鏈狀之碳數8之醯基、取代或無 取代之直鏈或支鏈狀之碳數1〜6之烷氧基羰基、取代或 無取代之苯基羰基、碳數1〜6之直鏈或支鏈狀之烷硫基 、二鹵素甲基或三鹵素甲氧基{作爲B3之取代基者如:齒 素原子、羥基、胺基、羧基、硝基、氰基、直鏈或支鏈狀 -15- 200916098 之碳數1〜6之烷基、直鏈或支鏈狀之碳數1〜6之院氧基 (作爲取代基’鄰接之2個烷氧基亦可形成縮醛鍵)、三 鹵素甲基、或三鹵素甲氧基。此等亦可於任意之位置以i 個或多數個各自獨立取代}; Z代表碳原子或氮原子; Q代表碳原子或氮原子。] 作爲本發明之碳數丨〜6之直鏈、支鏈狀、或環狀之 院基者如:甲基、乙基、(n-,i-)丙基、2,2 -二甲基丙基 、(n-,i-,t-) 丁基、1,1-二甲基丁基、n_戊基、環己基等 例。作爲碳數1〜4之烷基者係指此等中碳數爲i〜4者; 具體例如:甲基、乙基、(n-,i -)丙基、(η-, i-, s_, t-)丁基之例。 作爲本發明之直鏈或支鏈狀之碳數1〜6之烷氧基者 ’其具體例如:甲氧基、乙氧基、(η-, i-)丙氧基、(11_ ,i-,s-, t-) 丁氧基等例。作爲碳數1〜4之烷氧基者爲相 同於上述之院基,係指此等中碳數爲1〜4者。 作爲本發明之碳數1〜7之直鏈或支鏈狀之伸烯基者 如:乙烯基、丙烯基、丁烯基、戊烯基等例。 作爲本發明之碳數6〜11之芳基者如:苯基、萘基等 例。碳數7〜1 1之伸芳基係指此等中碳數爲7〜Η者。 本發明中’作爲環上具有1個以上選自氧原子、氮原 子及硫原子所成群之雜原子之碳數4〜10之雜伸芳基者, 具體例如:呋喃基、噻嗯基' 嘧啶基、苯並呋喃基、苯並 咪唑基、喹啉基、異喹啉基、喹喔啉基、苯並噁二唑基、 -16- 200916098 苯並噻二唑基、吲哚基、苯並噻唑基、苯並 異噁唑基等例。 作爲本發明之鹵素原子例者如:氟原子 原子、碘原子之例。 作爲本發明之直鏈或支鏈狀之碳數1〜 ,具體例如:甲硫基、乙硫基、(η -, i -) i-,s_, t-) 丁硫基等例。 作爲本發明之直鏈、或支鏈狀之碳數1 支鏈狀之烷基磺醯基者,具體例如:甲基磺 酸基、(n·,i-)丙基擴醯基、(n-,i-, s-, 基之例。 #發明之取代或無取代之直鏈或支鏈出 之烷氧基羰基例者,如:甲氧基羰基、乙氧 i_)丙氧基簾基、(n-,i-,s-, t-) 丁氧基鑛: 作爲本發明之直鏈或支鏈狀之碳數1〜 •乙酿基、乙基鑛基、(η-, i-)丙基鑛基 t-)羰基等例。 作爲本發明之直鏈或支鏈狀之碳數1〜 者’具體例如:乙醯胺基、乙基羰基胺基、 鑛基胺基、(n-,i-, s_,t_ )羰基胺基等例。 作爲本發明之三鹵素甲基之具體例者如 二溴甲基、三氯甲基之例。 作爲本發明之三鹵素甲氧基之具體例者 基、三溴甲氧基、三氯甲氧基之例。 噻嗯基、苯並 、氯原子、溴 6之烷硫基者 丙硫基、(n-, 〜6之直鏈或 醯基、乙基磺 t- ) 丁基磺醯 ^之碳數1〜6 基羯基、(η-, _等例。 6之醯基者如 、(η-, i-, s-, 6之酿基胺基 (η-, i-)丙基 :三氟甲基、 如:三氟甲氧 -17- 200916098 又’作爲式(I )所示之含氮芳香環衍生物者, R1及R2代表同時或各自獨立之氫原子、甲基或鹵素 原子; A代表單鍵、取代或無取代之碳數1〜5之直鏈、環 狀或支鏈狀之伸烷基;E代表-COOR3、-S03R3、-CONHR3 、-S02NHR3、四唑-5_基、5•氧基H4-噁二唑-3_基、或 5_氧基-1,2,4-噻二唑_3_基(其中,R3代表氫原子或直鏈或 支鏈狀之碳數1〜6之院基); G代表取代或無取代之碳數〗〜3之直鏈或支鏈狀之 伸烷基’該G之伸烷基所具有之取代基爲鹵素原子、羥基 、硝基 '氰基、直鏈或支鏈狀之碳數1〜6之烷基、直鏈 或支鏈狀之碳數1〜6之烷氧基(作爲取代基,鄰接之2 個烷氧基亦可形成縮醛鍵)、三鹵素甲基、三鹵素甲氧基 、苯基、或氧基; Μ代表單鍵或_S(0)m_’ m爲〇〜2之整數; J代表取代或無取代之(環上具有1個以上選自氧原 子、氮原子、及硫原子所成群之雜原子之碳數4〜10之雜 芳基或萘基),該J之雜芳基或萘基可具有之取代基爲鹵 素原子、羥基、硝基、氰基、直鏈或支鏈狀之碳數1〜6 之烷基、直鏈或支鏈狀之碳數1〜6之烷氧基(作爲取代 基’鄰接之2個烷氧基亦可形成縮醛鍵)、直鏈或支鏈狀 之碳數1〜6之烷硫基、直鏈或支鏈狀之碳數1〜6之烷基 磺醯基、直鏈或支鏈狀之碳數1〜6之醯基、直鏈或支鏈 狀之碳數1〜6之醯基胺基、取代或無取代之醯替苯胺基 -18- 200916098 、三鹵素甲基、三鹵素甲氧基、苯基、氧基、C〇〇R3基、 或以1個以上之鹵素原子所取代亦可之苯氧基,此等取代 基亦可於環之任意位置以1個或多數個各自獨立取代; X代表-CH =或氮原子; Y代表-CB =或氮原子; B係以-B 1 - B2 - B3示之; B1代表單鍵或直鏈或支鏈狀之碳數1〜3之伸院基· B2代表單鍵、-CO-或-NR3-; β3代表氫原子、鹵素原子、羥基、磺酿基、取代或無 取代之碳數卜6之烷基、取代或無取代之碳數卜6之烷 氧基、取代或無取代之碳數6〜^ <方基、取代或無取代 之胺基、取代或無取代之殘基、取代 5 ^ 代或無取代之碳數1〜6 之院基磺醯基、取代或無取代之苯 ^ ^ ^ 棊砀醯基、取代或無取 代e 數1〜6之胺基磺醯基、取什 々硫I w 代或無取代之碳數1〜8 之醱基、取代或無取代之碳數1〜6 仵甙你而+ _ 之烷氧基羰基、或取 代戈,,、、取代之本基羰基。{作爲β3 子、-»、# # , <取代基者如:鹵素原 丁 L基、fe數丨〜6之烷基、胺 /Τ. , 或羧基。此等亦可於 tt思位置以1個或多數個各自獨立 乂月乂代1 . Z爲碳原子; > ’ Q爲氮原子者宜。 Q爲氮原子時,以 另外,式(I)中,z爲碳原子且 下式(I) -II示之。 -19- 200916098 【化3】[In the formula (I), R1 and R2 represent a hydrogen atom, a halogen atom, a trihalomethyl group, a cyano group, a hydroxyl group, a linear or branched carbon number of 丨~4 or a linear chain which are simultaneously or independently. Or a branched carbon number 4 alkoxy group, or ... and R2 is a linked-0-CH2-0-, -0-CH2-CH2-0-^-ch2-ch2-ch2-R1 and R are a linkage The carbon number may also be substituted by one or more linear or branched alkyl groups having 1 to 4 carbon atoms; a linear chain of 1 to 6 and a single bond representing a substituted or unsubstituted carbon. -12-200916098 branched or cyclic alkyl, substituted or unsubstituted aryl group having 6 to n carbon atoms, or substituted or unsubstituted, having at least one oxygen atom selected from the ring, a hetero atom having a carbon atom of 4 to 10 in a hetero atom of a group of nitrogen atoms and a sulfur atom. {As a substituent of A, such as a halogen atom, a hydroxyl group, a nitro group, a cyano group, a linear or branched carbon. An alkyl group having 1 to 6 alkyl groups, a linear or branched alkoxy group having 1 to 6 carbon atoms (as a substituent, two adjacent alkoxy groups may form a waking bond), a linear or branched chain Carbon number 1 to 6 alkylthio, linear or branched carbon number 1 An alkylsulfonyl group of 6 or a linear or branched fluorenyl group having 1 to 6 carbon atoms, a linear or branched carbon group having 1 to 6 carbon atoms, a trihalomethyl group, a trihalogen group An oxy group, a phenyl group, an oxy group, or a phenoxy group which may be substituted by one or more halogen atoms. These may also be independently substituted by one or more at any position of the ring or alkylene group. E represents -COOR3, -S03R3, -CONHR3, -SO2NHR3, tetrazolyl, 5-oxy-1,2,4 -oxadiazolyl or 5-oxy-1,2,4-thiadiazolyl (R3 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms); G represents a substituted or unsubstituted The linear or branched alkyl group having a carbon number of 1 to 6 may also contain one or a plurality of ruthenium, S, S02, and NR3 in the middle. {R3 is the same as the definition of V above. As a substituent of G, for example, a halogen atom, a trans group, a nitro group, an amino group, a linear bond or a branched bond having 1 to 6 carbon atoms, a linear or branched alkoxy group having 1 to 6 carbon atoms a group (as a substituent, two alkoxy groups adjacent to each other may also form an acetal ether), a trihalomethyl group, a trihalomethoxy group, a phenyl group, or an oxy}; M represents a single bond or -S(0) M-, m represents an integer of 〇~2; J represents a linear-13-200916098, cyclic or branched alkyl group when m is 0 and A is a substituted or unsubstituted carbon number of 1 to 6 Substituted or unsubstituted, linear, cyclic or branched alkyl having 3 to 6 carbon atoms, substituted or unsubstituted, aryl having 7 to 11 carbon atoms, or substituted or unsubstituted, having 1 ring on the ring The above heteroaryl group having a carbon number of 4 to 1 Å selected from the group consisting of an oxygen atom, a nitrogen atom, and a hetero atom in a group of sulfur atoms. J represents a group in which m is fluorene and a represents a substituted or unsubstituted aryl group having 6 to n carbon atoms, or a substituted or unsubstituted group having at least one selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom. When the hetero atom has a carbon number of 4 to 10, the substituted aryl group is a substituted or unsubstituted carbon number of 1 to 6 linear, cyclic or branched, substituted or unsubstituted carbon number 6 to 11 The aryl group or the substituted or unsubstituted ring has a heterocyclic group having 4 or more carbon atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom. J. When Μ is a single bond, „1 is 〇 and a is a single bond, or 〇1 is 1 or 2', it represents a substituted or unsubstituted linear, cyclic or branched base of 1 to 6 carbon atoms. a substituted or unsubstituted carbon number of 6 to aryl groups, or a substituted or unsubstituted ring having one or more carbon atoms selected from the group consisting of oxygen atoms, nitrogen atoms, and sulfur atoms. Heteroaryl. {Substituent for J: halogen atom, hydroxyl group, nitro group, cyano group, linear or branched alkyl group having 1 to 6 carbon atoms, linear or branched carbon number 1 Alkoxy group of ~6 (as a substituent, two alkoxy groups adjacent thereto may also form an acetal bond), a linear or branched carbon number! ~6 alkylthio group, a straight bond or a branched chain Alkylsulfonyl having 1 to 6 carbon atoms, a linear or branched fluorenyl group having 1 to 6 carbon atoms, a linear or branched decylamino group having 1 to 6 carbon atoms, substituted or unsubstituted Further, an anilino group, a tridentate methyl group, a trihalomethyl-14-200916098 oxy group, a phenyl group, an oxy group, a COOR3 group (R3 is the same as defined in the above R3), or a halogen atom substituted by one or more Phenoxy group, this can also be in the ring Or any position of the alkyl group is independently substituted by one or a plurality of each;} X represents -CH = or a nitrogen atom; Y represents -CB = or a nitrogen atom; and B is represented by -B 1 -B 2 - B 3 ; B 1 represents a single bond or a straight or branched alkyl group having 1 to 3 carbon atoms; B 2 represents a single bond, -CO- or -NR 3 (wherein R 3 is the same as defined above); B 3 represents hydrogen Atom, a halogen atom, a nitro group, a cyano group, a hydroxy group, a sulfonyl group, a substituted or unsubstituted linear or branched alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted linear or branched chain. An alkoxy group having 1 to 6 carbon atoms, a substituted or unsubstituted aryl group having 6 to 11 carbon atoms, a substituted or unsubstituted ring having at least one selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom a heteroaryl group having 4 to 10 carbon atoms, a substituted or unsubstituted amino group, a substituted or unsubstituted carboxyl group, a substituted or unsubstituted linear or branched carbon number of 1 to 6 , substituted or unsubstituted phenylsulfonyl, substituted or unsubstituted, straight or branched, aminoalkylsulfonyl having 1 to 6 carbon atoms, substituted or unsubstituted straight or branched chain Carbon number 8 a substituted or unsubstituted linear or branched alkoxycarbonyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenylcarbonyl group, a linear or branched alkylthio group having 1 to 6 carbon atoms, Dihalomethyl or trihalogen methoxy {as a substituent for B3 such as: dentate atom, hydroxyl group, amine group, carboxyl group, nitro group, cyano group, linear or branched -15- 200916098 carbon number 1 ~6 alkyl, linear or branched carbon having 1 to 6 carbon atoms (the two alkoxy groups adjacent to the substituent ' may also form an acetal bond), a trihalomethyl group, or a trihalogen Methoxy. These may also be independently substituted by i or a plurality of positions at any position}; Z represents a carbon atom or a nitrogen atom; and Q represents a carbon atom or a nitrogen atom. As a linear, branched or cyclic base of the carbon number 丨~6 of the present invention, such as methyl, ethyl, (n-, i-) propyl, 2,2-dimethyl Examples of propyl, (n-, i-, t-) butyl, 1,1-dimethylbutyl, n-pentyl, cyclohexyl and the like. The alkyl group having a carbon number of 1 to 4 means that the number of carbon atoms in the group is i to 4; specifically, for example, methyl group, ethyl group, (n-, i-) propyl group, (η-, i-, s_) , t-) butyl case. As the linear or branched alkoxy group having 1 to 6 carbon atoms of the present invention, it specifically includes, for example, a methoxy group, an ethoxy group, (η-, i-) propoxy group, (11_, i-). , s-, t-) butoxy group and the like. The alkoxy group having 1 to 4 carbon atoms is the same as the above-mentioned hospital base, and means that the number of carbon atoms in the group is 1 to 4. The linear or branched alkylene group having a carbon number of 1 to 7 of the present invention is exemplified by a vinyl group, a propenyl group, a butenyl group or a pentenyl group. Examples of the aryl group having a carbon number of 6 to 11 in the present invention include a phenyl group and a naphthyl group. The aryl group having a carbon number of 7 to 1 1 means that the number of carbon atoms in the group is 7 to Η. In the present invention, 'a heterocyclic aryl group having 4 to 10 carbon atoms which has one or more hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom, and specifically, for example, a furyl group or a thiol group. Pyrimidinyl, benzofuranyl, benzimidazolyl, quinolyl, isoquinolinyl, quinoxalinyl, benzooxadiazolyl, -16- 200916098 benzothiadiazolyl, fluorenyl, benzene And thiazolyl, benzoisoxazolyl and the like. Examples of the halogen atom of the present invention include a fluorine atom atom and an iodine atom. The linear or branched carbon number of the present invention is, for example, a methylthio group, an ethylthio group, (η -, i -) i-, s_, t-) butylthio group, and the like. As the linear or branched carbon number 1-branched alkylsulfonyl group of the present invention, specifically, for example, a methylsulfonic acid group, an (n·,i-)propyl propyl group, (n) -, i-, s-, an example of a base. #例的取代或非分的直链或支链的醇氧carbonyl, such as: methoxycarbonyl, ethoxy i_) propoxy curtain , (n-, i-, s-, t-) butoxy ore: as a linear or branched carbon number of the present invention 1~ • ethyl, ethyl or, (η-, i- Propyl ore t-) carbonyl and the like. The linear or branched carbon number 1 to 'for example of the present invention' is specifically, for example, an acetamino group, an ethylcarbonylamino group, a ore group, and an (n-, i-, s-, t-)carbonylamino group. Etc. Specific examples of the trihalomethyl group of the present invention include dibromomethyl and trichloromethyl. Specific examples of the trihalomethoxy group of the present invention include a tribromomethoxy group and a trichloromethoxy group. Thiol group, benzo, chlorine atom, bromine 6 alkylthio group propylthio group, (n-, -6 straight or fluorenyl, ethyl sulfonate t-) butyl sulfonate ^ carbon number 1~ 6 羯 羯, (η-, _ et al. 6 醯 base such as, (η-, i-, s-, 6 tyrosylamino (η-, i-) propyl: trifluoromethyl For example, trifluoromethoxy-17-200916098 and 'as a nitrogen-containing aromatic ring derivative represented by formula (I), R1 and R2 represent a hydrogen atom, a methyl group or a halogen atom which are simultaneously or independently; A represents a single A linear, cyclic or branched alkyl group having 1 to 5 carbon atoms; a substituted or unsubstituted alkyl group; E represents -COOR3, -S03R3, -CONHR3, -S02NHR3, tetrazol-5-yl, 5• Oxy-H4-oxadiazol-3-yl or 5-oxy-1,2,4-thiadiazole-3-yl (wherein R3 represents a hydrogen atom or a linear or branched carbon number of 1~ 6 represents a substituted or unsubstituted carbon number of 〜3 of a straight or branched alkyl group. The substituent of the G alkyl group has a halogen atom, a hydroxyl group, a nitro group. a cyano group, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched alkoxy group having 1 to 6 carbon atoms (as a a group, the adjacent two alkoxy groups may also form an acetal bond), a trihalomethyl group, a trihalomethoxy group, a phenyl group, or an oxy group; Μ represents a single bond or _S(0)m_' m is 〇 An integer of ~2; J represents a substituted or unsubstituted (heteroaryl or naphthyl group having from 4 to 10 carbon atoms having one or more hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom) The heteroaryl or naphthyl group of J may have a halogen atom, a hydroxyl group, a nitro group, a cyano group, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched chain. Alkoxy groups having 1 to 6 carbon atoms (the two alkoxy groups adjacent to the substituent ' may also form an acetal bond), linear or branched alkylthio groups having 1 to 6 carbon atoms, straight or branched Alkylsulfonyl group having a carbon number of 1 to 6 in a chain form, a linear or branched fluorenyl group having 1 to 6 carbon atoms, a linear or branched carbon group having 1 to 6 carbon atoms, and a substitution Or unsubstituted hydrazine substituted phenylamino-18- 200916098, trihalomethyl, trihalomethoxy, phenyl, oxy, C〇〇R3 group, or substituted with one or more halogen atoms Oxyl group, these substituents may also be in the ring Any position is independently substituted by 1 or a plurality; X represents -CH = or a nitrogen atom; Y represents -CB = or a nitrogen atom; B is represented by -B 1 - B2 - B3; B1 represents a single bond or a linear chain Or a branched carbon number of 1 to 3; B2 represents a single bond, -CO- or -NR3-; β3 represents a hydrogen atom, a halogen atom, a hydroxyl group, a sulfonyl alcohol group, a substituted or unsubstituted carbon number 6 alkyl, substituted or unsubstituted carbon number 6 alkoxy, substituted or unsubstituted carbon number 6~^ < aryl, substituted or unsubstituted amino group, substituted or unsubstituted residue, a substituted sulfonyl group having 1 to 6 carbon atoms, an unsubstituted or unsubstituted benzene group, a substituted or unsubstituted amino group sulfonyl group having 1 to 6 carbon atoms, What is the sulfonium I w or unsubstituted carbon number 1 to 8 fluorenyl group, substituted or unsubstituted carbon number 1 to 6 仵甙 you and + _ alkoxycarbonyl group, or substituted Ge,,,, substituted The base carbonyl group. {As β3, -», ##, <Substituents such as: halogen, butyl, aryl, aryl, hydrazine, or carboxy. These may also be in the position of tt, in which one or more of them are independent of each other. Z is a carbon atom; > 'Q is a nitrogen atom. When Q is a nitrogen atom, in the formula (I), z is a carbon atom and is represented by the following formula (I)-II. -19- 200916098 【化3】
更作爲式(I)所不之含氮芳香環衍生物者, R1及R2代表同時或各自獨立之氫原子、甲基或鹵素 原子;A爲取代或無取代之碳數1〜5之直鏈、環狀或支 鍵狀之伸院基;E 爲-COOR3、-S03R3、-CONHR3、_ S02NHR3、四哩-5-基、5 -氧基 _1,2,4·α惡二唑 _3·基、或 5_ 氧基-1,2,4-噻二唑-3-基(其中’ R3代表氫原子或直鏈或 支鏈狀之碳數1〜6之烷基);G代表取代或無取代之碳 數1〜3之直鏈或支鏈狀之伸烷基,該G之伸院基可具有 之取代基爲鹵素原子、羥基 '硝基、氰基、直鏈或支鏈狀 之碳數1〜6之烷基、直鏈或支鏈狀之碳數丨〜6之烷氧基 (作爲取代基,鄰接之2個烷氧基亦可形成縮醛鍵)、三 鹵素甲基、三鹵素甲氧基、苯基、或氧基;Μ代表單鍵 或-S(0)m-,m爲0〜2之整數;J代表取代或無取代之( 環上具有1個以上選自氧原子、氮原子及硫原子所成群之 雑原子之碳數4〜10之雜方基)’該J之雜芳基所具有之 取代基爲_素原子、經基、硝基·氰基’直鏈或支鏈狀之 碳數1〜6之烷基、直鏈或支鏈狀之碳數1〜6之烷氧基( 作爲取代基,鄰接之2個烷氧基亦可形成縮醛鍵)、直鏈 或支鏈狀之碳數1〜6之烷硫基、直鏈或支鏈狀之碳數1〜 6之烷基磺醯基、直鏈或支鏈狀之碳數1〜6之醯基、直鏈 -20- 200916098 或支鏈狀之碳數1〜6之醯基胺基、取代或無取代之酸替 苯胺基、三鹵素甲基、三鹵素甲氧基、苯基、氧基、 COOR3基、或以1個以上之鹵素原子所取代亦可之苯氧基 。此等取代基亦可於環之任意位置以1個或多數個各自獨 立取代;X爲-CH =或氮原子;Y爲氮原子者宜。 更,作爲式(I)所示之含氮芳香環衍生物者, R1及R2代表同時或各自獨立之氫原子、甲基或鹵素 原子;A爲取代或無取代之碳數3〜5之直鏈、環狀、或 支鏈狀之伸烷基;E爲-COOR3 (其中’ R3代表氫原子或 直鏈或支鏈狀之碳數1〜6之烷基);G代表甲撐基;Μ 代表-S- ; J代表取代或無取代之苯並噻嗯基或Ν-甲基卩引哚 基,該J之雜芳基可具有之取代基爲鹵素原子、直鏈或支 鏈狀之碳數1〜3之烷基、三齒素甲基、或氧基;χ爲-CH=; Υ爲氮原子者更佳。 進一步,作爲式(I )所示之含氮芳香環衍生物者’ 爲下述之構造式所示之化合物者宜’此等化合物亦具有阻 礙酵素製劑活性。 -21 - 200916098 【化4】Further, as a nitrogen-containing aromatic ring derivative which is not a formula (I), R1 and R2 represent a hydrogen atom, a methyl group or a halogen atom which are simultaneously or independently, and A is a substituted or unsubstituted linear chain having a carbon number of 1 to 5. , ring or branch-shaped extension of the base; E is -COOR3, -S03R3, -CONHR3, _S02NHR3, tetradec-5-yl, 5-oxo-1,2,4·αoxadiazole_3 · a group, or a 5-oxy-1,2,4-thiadiazol-3-yl group (wherein 'R3 represents a hydrogen atom or a straight or branched alkyl group having 1 to 6 carbon atoms); G represents a substitution or An unsubstituted linear or branched alkyl group having 1 to 3 carbon atoms, and the substituent of the G may have a halogen atom, a hydroxyl group 'nitro group, a cyano group, a linear chain or a branched chain. An alkyl group having 1 to 6 carbon atoms, a linear or branched alkoxy group having a carbon number of 丨~6 (as a substituent, two alkoxy groups adjacent thereto may form an acetal bond), a trihalomethyl group, Trihalomethoxy, phenyl, or oxy; Μ represents a single bond or -S(0)m-, m is an integer from 0 to 2; J represents a substituted or unsubstituted (having one or more selected from the ring) Heterogeneous carbon with a carbon number of 4 to 10 in the group of oxygen atoms, nitrogen atoms and sulfur atoms The substituent of the heteroaryl group of the J is a silane atom, a benzyl group, a nitro-cyano group, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched chain. Alkoxy group having 1 to 6 carbon atoms (as a substituent, two alkoxy groups adjacent thereto may also form an acetal bond), a linear or branched alkylthio group having 1 to 6 carbon atoms, a linear chain or A branched alkyl sulfonyl group having 1 to 6 carbon atoms, a linear or branched fluorenyl group having 1 to 6 carbon atoms, a linear chain of -20-200916098 or a branched carbon number of 1 to 6 An amino group, a substituted or unsubstituted acid anilide, a trihalomethyl group, a trihalomethoxy group, a phenyl group, an oxy group, a COOR 3 group, or a phenoxy group substituted by one or more halogen atoms . These substituents may also be independently substituted at one or a plurality of positions at any position of the ring; X is -CH = or a nitrogen atom; and Y is preferably a nitrogen atom. Further, as the nitrogen-containing aromatic ring derivative represented by the formula (I), R1 and R2 represent a hydrogen atom, a methyl group or a halogen atom which are simultaneously or independently, and A is a substituted or unsubstituted carbon number of 3 to 5; a chain, a cyclic, or a branched alkyl group; E is -COOR3 (wherein 'R3 represents a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms); and G represents a methylene group; Representative: -S-; J represents a substituted or unsubstituted benzoxyl or fluorenyl-methyl fluorenyl group, and the heteroaryl group of J may have a halogen atom, a linear or branched carbon Alkyl groups of 1 to 3, tridentate methyl or oxy; hydrazine is -CH=; hydrazine is preferably a nitrogen atom. Further, the compound of the nitrogen-containing aromatic ring derivative represented by the formula (I) is preferably a compound represented by the following structural formula, and these compounds also have an activity of inhibiting the enzyme preparation. -21 - 200916098 【化4】
上述化合物中又以下述構造式所示之化合物爲較佳。 -22 - 200916098Among the above compounds, a compound represented by the following structural formula is preferred. -22 - 200916098
αα
VsVs
COOHCOOH
上述中更以4-(1-( (4_甲基苯並噻吩-3_基)甲基) 苯並咪唑-2-硫代)丁酸或4-(1-( (4 -甲基-卜氧基苯並 嚷吩-3-基)甲基)苯並咪唑-2_硫代)丁酸爲較佳,特別 以4-(1-( (4 -甲基苯並噻吩_3_基)甲基)苯並咪唑_2_ 硫代)丁酸爲最理想。 又’上述式(I)中’ R1及r2代表氫原子;A代表取 代或無取代之碳數〗〜5之直鏈、環狀、或支鏈狀之伸烷 基;E代表-COOR3 (其中,R3爲氫原子或直鏈或支鏈狀 之碳數1〜6之烷基);G代表甲撐基;M代表, 如爲0〜2之整數;J代表取代或無取代之苯並噻嗯基,該 笨並噻嗯基可具有之取代基爲直鏈或支鏈狀之碳數1〜3 之院基或氧基;X爲-c Η γ爲氮原子亦爲理想者: 以上式(I )所示之Ϊ里想的化合物中各自之基亦以各 自之基分別代表之。亦即,如:作爲R1及R2者代表同時 ’或各自獨立之氫原子、甲基或鹵素原子;R1及R2代表 同時爲氫原子、甲基或氯原子;Rl及R2爲氫原子;作爲 -23- 200916098 理想基之例。 有關含有下述式(11)所示之含氮芳香環衍生物或其 醫學上可容許之鹽爲有效成分之藥劑亦可期待適用於 URA Τ 1 P且礙齊1ί ;降低尿酸値用劑;痛風、高尿酸血症、或 尿酸相關疾病(如:痛風關節炎、痛風結節、尿路結石、 腎結石、腎障礙、痛風腎、心血管疾病、或腦血管疾病) 之預防劑或治療劑;伴隨痛風或高尿酸血症之心臟病(如 :心肥大、心臟衰竭、或心肌梗塞)之預防劑或治療劑; 伴隨痛風或高尿酸血症之腎臟病(如:糖尿病性腎症、腎 衰竭、腎病、或腎炎)之預防劑或治療劑。In the above, 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazole-2-thio)butyric acid or 4-(1-((4-methyl-)- Phenoxybenzoin-3-yl)methyl)benzimidazole-2_thio)butyric acid is preferred, especially 4-(1-((4-methylbenzothiophene)-3-yl) )methyl)benzimidazole_2_thio)butyric acid is most desirable. Further, in the above formula (I), 'R1 and r2 represent a hydrogen atom; A represents a linear or cyclic alkyl group having a substituted or unsubstituted carbon number of 〜5; and E represents -COOR3 (wherein , R 3 is a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms; G represents a methylene group; M represents an integer of 0 to 2; and J represents a substituted or unsubstituted benzothiazide. That is, the stupid and thiophenanyl group may have a linear or branched carbon number of 1 to 3 or a oxy group; X is -c Η γ is also a desirable nitrogen atom: The respective groups of the compounds of the formula (I) are also represented by their respective groups. That is, for example, R1 and R2 represent simultaneously or independently hydrogen atoms, methyl or halogen atoms; R1 and R2 represent a hydrogen atom, a methyl group or a chlorine atom; R1 and R2 are hydrogen atoms; 23- 200916098 Example of ideal base. The agent containing a nitrogen-containing aromatic ring derivative represented by the following formula (11) or a medically acceptable salt thereof as an active ingredient can also be expected to be suitable for use in URA Τ 1 P and to reduce the use of uric acid bismuth; a prophylactic or therapeutic agent for gout, hyperuricemia, or a uric acid-related disease (eg, gout arthritis, gout nodules, urinary calculi, kidney stones, renal disorders, gout kidney, cardiovascular disease, or cerebrovascular disease); A prophylactic or therapeutic agent for heart disease (eg, cardiotrophy, heart failure, or myocardial infarction) associated with gout or hyperuricemia; kidney disease associated with gout or hyperuricemia (eg, diabetic nephropathy, renal failure) , a preventive or therapeutic agent for kidney disease, or nephritis.
[式(II)中’ R1及R2代表同時,或各自獨立之氫原 子、歯素原子、三鹵素甲基、氰基、羥基、碳數1〜4之 院基、碳數1〜4之烷氧基、或R1及R2爲連接之-0-CH2-0-、_0-CH2CH2-〇_ 或-Ch2ch2CH2_(ri 及 R2 爲連接時, 該碳原子亦可被1個或多數個碳數1〜4之烷基所取代) t A代表取代或無取代之碳數1〜7之直鏈、環狀、或[In the formula (II), 'R1 and R2 represent a hydrogen atom, a halogen atom, a trihalomethyl group, a cyano group, a hydroxyl group, a carbon number of 1 to 4, and a carbon number of 1 to 4, respectively. The oxy group, or R1 and R2 are the linked-0-CH2-0-, _0-CH2CH2-〇_ or -Ch2ch2CH2_ (where ri and R2 are attached, the carbon atom may also be 1 or a plurality of carbon atoms 1~ Substituted by an alkyl group of 4) t A represents a substituted or unsubstituted carbon number of 1 to 7 in a straight chain, a ring, or
支鏈狀之伸烷基或伸烯基,途中亦可含有1個或多數個-〇-、 -S-、 -SO ' -NR3-(其中,R3代表氫原子或直鏈或 -24- 200916098 支鏈狀之碳數1〜6之烷基)。A之取代基爲鹵素原子、 羥基、硝基、氰基、直鏈或支鏈狀之碳數丨〜6之院基、 直鏈或支鏈狀之碳數1〜6之烷氧基(包含所鄰接之2個 形成縮醛鍵時)、直鏈或支鏈狀之碳數1〜6之垸硫基、 直鏈或支鏈狀之碳數1〜6之院基磺醯基、直鏈或支鏈狀 之碳數1〜6之醯基、直鏈或支鏈狀之碳數丨〜6之醯基胺 基、三鹵素甲基、三鹵素甲氧基、苯基、氧基、或被〗個 以上之鹵素原子取代亦可之苯氧基。此等取代基亦可於伸 烷基或伸烯基之任意位置以1個或複數個各自獨立取代。 E 代表-COOR3 ' -S03R3、-CONHR3、-S02NHR3、四 唑基-5-基、5 -氧基-1,2,4-噁二唑-3-基、或 5 -氧基-1,2,4-噻二唑-3-基(其中,R3代表與上述R3相同); G代表取代或無取代之碳數1〜6之直鏈或支鏈狀之 伸烷基’途中亦可含有丨個或多數個-〇-、-S_、_S〇2_、-NR3-(其中,R3爲相同於上述r3之定義,含此等原子或 原子團時’此等未直接鍵結於含氮芳香環)。該伸烷基可 具有之取代基爲鹵素原子、羥基、硝基、氰基、直鏈或支 鏈狀之碳數1〜6之烷基、直鏈或支鏈狀之碳數1〜6之烷 氧基(包含,鄰接之2個爲形成縮醛鍵時)、三鹵素甲基 、三鹵素甲氧基 '苯基、或氧基; M代表單鍵或- S(0)m-,m爲0〜2之整數; J代表取代或無取代之(環上具有1個以上選自氧原 子、氮原子 '及硫原子所成群之雜原子之碳數4〜1 〇之雜 芳基)。 -25- 200916098 j之雜芳基可具有之取代基爲鹵素原子、羥基、硝基 、氰基、直鏈或支鏈狀之碳數1〜6之烷基、直鏈或支鏈 狀之碳數1〜6之烷氧基(包含,鄰接之2個爲形成縮醛 鍵時)、直鏈或支鏈狀之碳數1〜6之烷硫基、直鏈或支 鏈狀之碳數1〜6之烷基磺醯基、直鏈或支鏈狀之碳數1〜 6之醒基、直鏈或支鏈狀之碳數1〜6之醯基胺基、取代或 無取代之酿替苯胺基、二_素甲基、二鹵素甲氧基、苯基 、氧基、COOR3基、或以1個以上之鹵素原子取代亦可之 苯氧基。此等取代基亦可於環之任意位置以1個或多數個 各自獨立取代; X代表-CH =或氮原子。] 藉由本發明之式(I )所示化合物之投予後降低尿酸 値,因此’本發明之藥劑可適用於降低尿酸値用劑。更可 適用於痛風、高尿酸血症、痛風關節炎、痛風結節、尿路 結石、腎結石、腎障礙、痛風腎、心血管疾病、或腦血管 疾病等之尿酸相關疾病之預防劑或治療劑。 本發明有效成分之含氮芳香環衍生物除降低尿酸値作 用之外’亦具有阻礙酵素製劑活性。藉由此作用,本發明 之藥劑除降低尿酸値之外,亦可期待經由阻礙酵素製劑之 效果。 酵素製劑公知者如上述具多樣的生理活性,作爲其一 者如具有由Ang I往Ang II之轉換作用。Ang II係擔任維 持全身血壓、體液量等之生體內恆常性之重要功能之外, 亦對於心臟衰竭、心肌梗塞後之心臟機能障礙行進有重大 -26- 200916098 影響。基於此考量,A C E阻礙劑、高血壓蛋白寧受容體阻 礙劑顯示被開發作爲心臟衰竭及心肌梗塞後抑制心臟機能 障礙行進之治療藥有特定的治療效果。惟,人體心臟組織 中Ang II產生主要爲酵素製劑而非ACE,約80%出現源 於酵素製劑之Ang II,見證了心肌梗塞後心肌組織中出現 酵素製劑活性上昇。綜合考量此等後,被認爲阻礙酵素製 劑活性之藥劑對於抑制心臟衰竭及心肌梗塞後之心臟機能 障礙進行,具有可合理期待的治療效果。 加上酵素製劑,通過IL- 1 yS之活化,經由心血管障礙 部位之炎症反應惡化,複合蛋白酶之活化、纖維網蛋白、 IV型膠原的分解、細胞外蛋白質之分解、促進TGF- /3之 游離導致纖維芽細胞之分化增殖之機序中,亦被認爲有促 進心臟組織纖維化/心臟組織改變。心臟組織改變的進行 將導致長期生命預後惡化之重要因素,心臟組織改變的抑 制被大眾認爲重要的治療目標。 由上述,阻礙酵素製劑活性之藥劑,被認爲對於心臟 病(心臟肥大、心臟衰竭、或心肌梗塞)具有可合理期待 之治療效果。 又,含有酵素製劑之肥脖細胞係於正常的腎臟中存在 尿細管間質、血管壁之外膜’而糖尿病性腎症、急速進行 性絲球體腎炎(RPGN )及IgA腎症等中伴隨纖維化病變 的進行,確定往病變部的集成。此等疾病中,更顯現纖維 化病變的程度、腎功能下降與肥胖細胞數的增加呈正比, 被認爲含有酵素製劑之肥胖細胞關係著各種腎臟病的病態 -27- 200916098 形成·進行。 另外,作爲酵素製劑主要之作用者,具有由Ang I往 Ang II之轉換作用,Ang II被認爲亦深深影響各種腎臓病 之病態形成。事實上,臨床上ACE阻礙劑、高血壓蛋白 寧受容體拮抗劑被作爲糖尿病性腎症之治療藥開發,顯示 特定的治療效果。作爲上述藥劑主要作用之一者,被認爲 係介著抑制腎組織之Ang II產生之TGF- /3出現亢進之抑 制作用而非於循環血中。惟,一般組織中主要之A n g 11產 生酵素被認爲爲酵素製劑,而非ACE。又,動物實驗中, 腎臟間質中之Ang Η濃度遙遙高於循環血中,伴隨腎症的 進行組織Ang 11濃度亦出現上昇。合倂此等考量後,被認 爲阻礙酵素製劑活性之藥劑,對於各種腎臟病可合理期待 具有治療效果。 加上,酵素製劑亦被認爲通過I L- 1点之活性化經由腎 血管障礙部位之炎症反應增加惡化、複合蛋白酶之活性化 、纖維網蛋白、IV型膠原之分解之細胞外蛋白質之分解 ’直S經由促進TGF- 之游離之纖維芽細胞之分化增殖 之機序中具有促進腎臟組織纖維化/變化。腎臟組織纖維 化/變化的進行係使長期預後之重要因素,抑制腎臟組織 變化的進行被大眾認爲重要的治療目標。 由以上’阻礙酵素製劑活性的藥劑,對於腎臟病(糖 尿病性腎症、腎衰竭、腎病、或腎炎)被認爲可合理期待 具有治療效果。 式(I)所示之化合物,可藉由專利文獻1等所記載 -28- 200916098 之方法進行合成。如:使3 -溴甲基-4 -甲基苯並唾吩與4-(苯並咪哩-2-硫代)丁酸甲酯於3級胺等之鹼的存在下, 於甲苯等之烴溶媒中進行偶合反應,取得4_ (卜((4_甲 基苯並噻吩-3-基)甲基)苯並咪唑硫代)丁酸甲酯。 此於四氫呋喃溶媒中,以氫氧化鈉水溶液等進行水解、中 和後’可取得4-(1-( (4-甲基苯並噻吩-3-基)甲基)苯 並咪唑· 2 -硫代)丁酸。 又’本發明化合物之4_ ( 1- (( 4-甲基-1-氧基苯並噻 吩-3-基)甲基)苯並咪唑-2-硫代)丁酸係可以本申請之 實施例5所載方法合成。4_(1-( (4 -甲基-1-氧基苯並唾 吩-3-基)甲基)苯並咪唑-2-硫代)丁酸中存在不齊中心 ’藉由此存在光學異構體。藉由實施例5所載之方法,4_ (1-( (4-甲基-1-氧基苯並噻吩_3_基)甲基)苯並咪唑_ 2-硫代)丁酸作成消旋體被取得,必要時藉由組成不對稱 反應、光學分割等方法,可取得分割分別的光學異構體。 本發明化合物,其毒性低、穩定性亦良好。 作爲本發明式(I )所示化合物之鹽者,於其分子中 存在鹼性基,因此,必要時可轉換成醫學上可容許之酸加 成鹽。作爲該酸者,如:鹽酸、溴化氫酸、硫酸、硝酸、 磷酸、碳酸等之無機鹽;或乙酸、檸檬酸、蘋果酸、草酸 、酒石酸、乳酸、馬來酸、延胡索酸、甲磺酸等之有機酸 等例。 又’作爲本發明式(I )所示化合物之鹽者,於其分 子中存在酸性基,因此,必要時可轉換成醫藥上可容許之 -29- 200916098 -。作爲該鹽者,如:非毒性之陽離子鹽,具體Branched alkyl or alkenyl group, may also contain one or more -〇-, -S-, -SO '-NR3- (wherein R3 represents a hydrogen atom or a straight chain or -24- 200916098 Branched carbon having 1 to 6 carbon atoms). The substituent of A is a halogen atom, a hydroxyl group, a nitro group, a cyano group, a linear or branched carbon number of 丨~6, a linear or branched alkoxy group having 1 to 6 carbon atoms (including When two adjacent acetal bonds are formed, a linear or branched carbon number of 1 to 6 is a thiol group, a linear or branched carbon number of 1 to 6 is a sulfonyl group, and a linear chain is used. Or a branched carbon group having 1 to 6 carbon atoms, a linear or branched carbon number of 醯~6, a mercaptoamine group, a trihalomethyl group, a trihalomethoxy group, a phenyl group, an oxy group, or A phenoxy group which may be substituted by more than one halogen atom. These substituents may also be independently substituted in one or a plurality of positions at any position of an alkyl group or an alkenyl group. E represents -COOR3 ' -S03R3, -CONHR3, -S02NHR3, tetrazolyl-5-yl, 5-oxy-1,2,4-oxadiazol-3-yl, or 5-oxy-1,2 , 4-thiadiazol-3-yl (wherein R3 represents the same as the above R3); G represents a substituted or unsubstituted, straight or branched alkyl group having 1 to 6 carbon atoms, which may also contain hydrazine Or a plurality of -〇-, -S_, _S〇2_, -NR3- (wherein R3 is the same as defined in the above r3, and when such atoms or groups are contained, these are not directly bonded to the nitrogen-containing aromatic ring) . The alkylene group may have a substituent of a halogen atom, a hydroxyl group, a nitro group, a cyano group, a linear or branched alkyl group having 1 to 6 carbon atoms, or a linear or branched carbon number of 1 to 6 Alkoxy (including, when two adjacent to form an acetal bond), trihalomethyl, trihalomethoxy 'phenyl, or oxy; M represents a single bond or -S(0)m-,m An integer of 0 to 2; J represents a substituted or unsubstituted (heteroaryl group having 1 or more carbon atoms selected from the group consisting of an oxygen atom, a nitrogen atom, and a hetero atom in a group of sulfur atoms) . -25- 200916098 The heteroaryl group of j may have a halogen atom, a hydroxyl group, a nitro group, a cyano group, a linear or branched alkyl group having 1 to 6 carbon atoms, a linear or branched carbon. Alkoxy groups of 1 to 6 (including when two adjacent ones form an acetal bond), linear or branched alkylthio groups having 1 to 6 carbon atoms, linear or branched carbon number 1 Alkylsulfonyl group of ~6, linear or branched carbon group of 1 to 6 ketone group, linear or branched decylamino group having 1 to 6 carbon atoms, substituted or unsubstituted An anilino group, a di-methyl group, a dihalomethoxy group, a phenyl group, an oxy group, a COOR3 group, or a phenoxy group which may be substituted by one or more halogen atoms. These substituents may also be independently substituted at one or a plurality of positions at any position of the ring; X represents -CH = or a nitrogen atom. By the administration of the compound of the formula (I) of the present invention, the uric acid bismuth is lowered, so that the agent of the present invention can be suitably used for the use of a urate-reducing agent. It is also suitable for prophylactic or therapeutic agents for uric acid-related diseases such as gout, hyperuricemia, gout arthritis, gout nodules, urinary calculi, kidney stones, kidney disorders, gout kidney, cardiovascular disease, or cerebrovascular diseases. . The nitrogen-containing aromatic ring derivative of the active ingredient of the present invention has a hindrance to the activity of the enzyme preparation in addition to lowering the action of uric acid. By this action, the agent of the present invention can be expected to have an effect of inhibiting the enzyme preparation in addition to reducing uric acid strontium. The enzyme preparation is known to have various physiological activities as described above, and one of them has a conversion action from Ang I to Ang II. The Ang II system plays an important role in maintaining the body's constant blood pressure, such as blood pressure and body fluid volume, and has a significant impact on cardiac dysfunction and cardiac dysfunction after myocardial infarction. Based on this consideration, the A C E inhibitor, the hypertensive protein receptor-containing barrier agent has been shown to have a specific therapeutic effect as a therapeutic drug for developing heart failure and inhibiting cardiac dysfunction after myocardial infarction. However, Ang II production in human heart tissue is mainly an enzyme preparation rather than ACE, and about 80% of Ang II derived from an enzyme preparation has witnessed an increase in the activity of an enzyme preparation in myocardial tissue after myocardial infarction. After comprehensive consideration of these factors, it is considered that the agent which inhibits the activity of the enzyme preparation has a therapeutic effect which is reasonably expected to be suppressed for the prevention of heart failure and cardiac dysfunction after myocardial infarction. In addition to the enzyme preparation, the activation of IL-1 yS deteriorates the inflammatory response through the cardiovascular site, the activation of the complex protease, the breakdown of fibrin, type IV collagen, the decomposition of extracellular proteins, and the promotion of TGF-/3. In the mechanism of free differentiation and proliferation of fibroblasts, it is also considered to promote cardiac tissue fibrosis/heart tissue changes. Progression of cardiac tissue changes will lead to an important factor in the deterioration of long-term life prognosis, and inhibition of cardiac tissue changes is considered an important therapeutic target. The above-mentioned agent which inhibits the activity of the enzyme preparation is considered to have a therapeutic effect which is reasonably expected for heart disease (cardiac hypertrophy, heart failure, or myocardial infarction). In addition, the fat neck cell line containing the enzyme preparation has a urinary tubule interstitial, a vascular wall outer membrane in a normal kidney, and a companion fiber in diabetic nephropathy, rapid progressive glomerulonephritis (RPGN), and IgA nephropathy. The progression of the lesion is determined to determine the integration into the lesion. Among these diseases, the degree of fibrotic lesions and the decrease in renal function are directly proportional to the increase in the number of obese cells. It is considered that the obese cells containing the enzyme preparation are involved in the pathology of various kidney diseases -27-200916098. In addition, as a major agent of the enzyme preparation, it has a conversion effect from Ang I to Ang II, and Ang II is considered to also deeply affect the pathological formation of various renal rickets. In fact, clinically, ACE inhibitors, hypertensive protein receptors have been developed as therapeutic agents for diabetic nephropathy, showing specific therapeutic effects. As one of the main effects of the above-mentioned agents, it is considered to inhibit the inhibition of TGF-/3 produced by Ang II produced by renal tissues rather than in circulating blood. However, the major A n g 11 producing enzymes in the general organization are considered to be enzyme preparations, not ACE. In addition, in the animal experiment, the concentration of Ang Η in the renal interstitial was much higher than that in the circulating blood, and the concentration of Ang 11 was also increased with the involvement of nephropathy. After considering these considerations, it is considered to be an agent that hinders the activity of the enzyme preparation, and it is expected to have a therapeutic effect for various kidney diseases. In addition, the enzyme preparation is also considered to be degraded by the activation of the I L-1 point through the inflammatory reaction of the renal vascular dysfunction, the activation of the complex protease, the decomposition of the extracellular protein of fibrin and the decomposition of type IV collagen. 'Straight S promotes renal tissue fibrosis/change in a sequence that promotes differentiation and proliferation of free fibroblasts that promote TGF-. Renal tissue fibrosis/change progression is an important factor in long-term prognosis, and inhibition of changes in kidney tissue is considered an important therapeutic target. The above-mentioned agent which inhibits the activity of the enzyme preparation is considered to have a therapeutic effect on kidney disease (diabetic nephropathy, renal failure, kidney disease, or nephritis). The compound of the formula (I) can be synthesized by the method of -28-200916098 described in Patent Document 1 or the like. For example, 3-bromomethyl-4-methylbenzoparaphene and methyl 4-(benzopyrene-2-thio)butanoate in the presence of a base such as a tertiary amine, in toluene, etc. The coupling reaction was carried out in a hydrocarbon solvent to obtain methyl 4-((4-methylbenzothiophen-3-yl)methyl)benzimidazolethio)butanoate. In the tetrahydrofuran solvent, hydrolysis is carried out with an aqueous solution of sodium hydroxide or the like, and after neutralization, 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazole·2-sulfurate can be obtained. Generation) butyric acid. Further, 4-(1-((4-methyl-1-oxybenzothiophen-3-yl)methyl)benzimidazole-2-thio)butanoic acid of the compound of the present invention may be an example of the present application 5 method synthesis. 4_(1-((4-methyl-1-oxybenzonaphen-3-yl)methyl)benzimidazole-2-thio)butyric acid exists in the presence of a misaligned center Structure. 4-(1-(4-methyl-1-oxobenzothiophene-3-yl)methyl)benzimidazole-2-thio)butyric acid was racemized by the method described in Example 5 The body is obtained, and if necessary, a separate optical isomer can be obtained by a method such as asymmetric reaction or optical division. The compound of the present invention has low toxicity and good stability. As the salt of the compound of the formula (I) of the present invention, a basic group exists in the molecule, and therefore, if necessary, it can be converted into a medically acceptable acid addition salt. As the acid, such as: inorganic salts of hydrochloric acid, hydrogen bromide, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, etc.; or acetic acid, citric acid, malic acid, oxalic acid, tartaric acid, lactic acid, maleic acid, fumaric acid, methanesulfonic acid Examples of organic acids and the like. Further, as the salt of the compound of the formula (I) of the present invention, an acidic group is present in the molecule, and therefore, if necessary, it can be converted into a pharmaceutically acceptable -29-200916098-. As the salt, such as: non-toxic cationic salt, specific
Na+、Κ+等之鹼金屬離子、 離子、Al3+、Ζη2 +等之金屬 胺、丙二胺、吡咯烷、六氫 賴氨酸(Lysine )、膽鹼、 4 -羥基六氫化吡啶、葡萄糖 鹼之鹽例。 本發明之有效成分,只 及液狀製劑等任意劑形、口 皮劑、點眼劑、栓劑、經鼻 製劑均可使用。 含有本發明有效成分之 添加劑所調製。作爲此等添 乳糖、白糖、葡萄糖、玉米 素、輕質無水矽酸、合成矽 鈣等之賦形劑;結晶纖維素 維素、羧甲基纖維素鈉、及 澱粉、羧甲基纖維素鈉、羧 維素鈉、及羧甲基澱粉鈉等 等之潤滑劑;羥甲基丙基纖 二甲酸酯及乙基纖維素等之 時’如:白色凡士林等基劑 劑 '乙醇等之溶解補助劑、 葡萄糖等之等張化劑、檸檬Metal amines such as Na+, Κ+, etc., metal ions, propylene, propylene glycol Salt case. The active ingredient of the present invention can be used in any dosage form such as a liquid preparation, a dermatological preparation, an eye drop, a suppository or a nasal preparation. It is prepared by an additive containing the active ingredient of the present invention. As such excipients for adding lactose, white sugar, glucose, zeatin, light anhydrous citric acid, synthetic strontium calcium, etc.; crystalline cellulose vegan, sodium carboxymethyl cellulose, and starch, sodium carboxymethyl cellulose Lubricants such as sodium carboxylate, sodium carboxymethyl starch, etc.; when hydroxymethylpropyl phthalate and ethyl cellulose are used, such as: base of white petrolatum, etc. Auxiliary agent, glucose, etc.
Mg2+、Ca2+、等之鹼土類金屬 離子、或氨、三乙胺、乙烯二 化耻Π定、六氫化舭P秦、姐D定、 乙醇胺、Ν,Ν-二甲基乙醇胺、 胺、Ν-甲基葡聚糖胺等與有機 要爲固形製劑、半固形製劑、 服劑及非口服劑(注射劑、經 劑、及吸入劑等)之任意適用 製劑係使用用於一般製劑化之 加劑者,爲固形製劑時,如: 澱粉、馬鈴薯澱粉、結晶纖維 酸鋁、矽酸鋁酸鎂、及磷酸氫 、羧甲基纖維素、羥基丙基纖 聚乙烯吡咯烷酮等之結合劑; 甲基纖維素鈣、交叉羧甲基纖 之崩散劑;滑石、及硬脂酸類 維素、羥甲基甲基纖維素鄰苯 塗層劑;著色劑;半固形製劑 ,液狀製劑時,如:乙醇等溶 對羥基苯甲酸酯等之保存劑、 酸類等之緩衝劑、L -抗壞血酸 -30 200916098 等之抗氧化劑、EDT A等之螯合劑、及聚山梨酸酯80等之 懸浮化劑、乳化劑等例。 本發明有效成分之投予量,一般爲1〜lOOOmg/每天 ’投予次數一般爲1〜3次/每天。 [實施例] 以下藉由實施例進行本發明具體的說明。惟,本發明 並未受限於此等實施例。 [實施例1 ] 健康成人男性之降低血中尿酸作用 於6名健康成人男性中,每天投予640mg之4-(1-( (4 -甲基苯並噻吩-3-基)甲基)苯並咪唑-2-硫代)丁酸 。圖1顯示對於開始投予前而言,投予7天後之血中尿酸 下降率。血中尿酸出現平均降低約-6 0 %之降低率。更顯示 算出尿酸之尿中排泄量時,對於投予開始前之尿中尿酸排 泄量出現增加。即使每天的投予量3 20mg,仍依用量依存 下顯示尿酸値下降作用。 由此結果顯示,4 - ( 1 - (( 4 -甲基苯並噻吩-3 -基)甲 基)苯並咪唑-2-硫代)丁酸可有效作爲尿酸値下降劑。 [實施例2] 使用人體URAT1發現細胞之尿酸輸送阻礙Alkaline earth metal ions of Mg2+, Ca2+, etc., or ammonia, triethylamine, ethylene diazepam, hexahydroquinone P Qin, sister D, ethanolamine, hydrazine, hydrazine-dimethylethanolamine, amine, hydrazine- Methyl dextran amine and the like, and any suitable preparations for solid preparation, semi-solid preparation, oral preparation, and parenteral preparation (injection, transdermal, and inhalation, etc.) are used for general formulation. For solid preparations, such as: starch, potato starch, crystalline aluminum silicate, magnesium silicate aluminate, and hydrogen phosphate, carboxymethyl cellulose, hydroxypropyl cellulose polyvinylpyrrolidone, etc.; methyl cellulose Calcium, cross-carboxymethylcellulose disintegrating agent; talc, and stearic acid vitamin, hydroxymethyl methylcellulose o-benzene coating agent; coloring agent; semi-solid preparation, liquid preparation, such as: ethanol A preservative such as a paraben or a buffer such as an acid, an antioxidant such as L-ascorbic acid-30 200916098, a chelating agent such as EDT A, or a suspension agent or an emulsifier such as polysorbate 80. example. The dosage of the active ingredient of the present invention is generally from 1 to 100 mg/day. The number of administrations is generally from 1 to 3 times per day. [Examples] Hereinafter, specific description of the invention will be made by way of examples. However, the invention is not limited to the embodiments. [Example 1] Lowering uric acid in blood of healthy adult males In 6 healthy adult males, 640 mg of 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzene was administered per day. And imidazole-2-thio)butyric acid. Figure 1 shows the rate of uric acid decline in blood after 7 days of administration before starting the administration. The average uric acid in the blood decreased by about -6 0%. Further, when the amount of urine excretion of uric acid was calculated, the amount of uric acid excretion in the urine before the start of administration increased. Even if the daily dose is 3 20 mg, it still shows a decrease in uric acid sputum depending on the dosage. From the results, it was revealed that 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazole-2-thio)butyric acid is effective as a bismuth urate reducing agent. [Example 2] Using human URAT1, cells were found to be obstructed by uric acid transport
三+ 田A 於發現媒介物PCDNA3.1進行人體URATl(hURATl )完全長cDNA之次克羅寧,經由利用lipofactamin 2000 -31 - 200916098 之核糖核蛋白體法’使人體URAT1基因複製至源於人體 目台兒腎細胞(Η E K 2 9 3細胞)。同時亦製作出僅複製發現 媒介物p c D N A 3 . 1之Η Ε Κ 2 9 3細胞(以下稱m 〇 c k細胞) 。選出藉由 geneticin耐性發現人體 URAT1基因之 HEK293細胞或mock細胞。與下述方法相同下證明將14C 所標識之尿酸輸送至細胞內’於指標中使人體URAT 1基 因出現機能。 利用調整於pH爲7_2±0.1之含有0.8% NaCM、0.04% KC1 ' 0.1% Glucose、0.034% NaHC03、0.02% EDTA-Na、 0.12% HEPES、0.05% Trypsin 之培養基,使人體 URAT1 發現HEK293細胞及mock細胞之培養細胞層進行游離, 利用含有10%牛胎兒血清之Dulbeccos’改性Eaglemedium 培養基(以下稱 D-MEM培養基),作成 4xl05cells/mL 濃度之細胞懸浮液。將作成105個/mL/we 11之人體UR ATI 發現HEK293細胞之懸浮液及m0Ck細胞之懸浮液播種於 24孔細胞培養皿,於d_mEM培養基中3 7°C下進行培養2 天後’進行以下的尿酸輸送阻礙試驗。 由各 well將培養基吸引去除後,將細胞置換爲 Hanks’ Balanced Salt Solution ( HBSS),於 37°C 下進行 約1 〇分鐘之預恆溫箱。將hb s s吸引去除後,添加含有 預先加溫至37t之各種濃度之4-(1-( (4-甲基苯並噻 吩-3-基)甲基)苯並咪唑-2_硫代)丁酸或4-(1-( (4-甲基-1-氧基苯並噻吩-3-基)甲基)苯並咪唑-2-硫代)丁 酸與輻射性配位基(所標識之尿酸··最後濃度i 0μΜ ) -32- 200916098 之溶液(以下稱1 4 C -尿酸溶液),於3 7 °c下進行5分鐘恆 溫保持’進行裝置反應。反應後,將μ c _尿酸溶液進行吸 引去除,以冰涼之HBSS進行洗淨3次。將人體URAT1 發現ΗΕΚ293細胞及mock細胞溶解於〇.imol/L之NaOH 水溶液(以下稱細胞樣品),由well採取,混合細胞樣 品與乳化閃爍器,以液體閃爍器計數器測定輻射活性。 將顯示UR AT 1特異性之尿酸輸送之輻射活性(實施 例化合物無添加(DMSO添加)之人體URAT1發現細胞 HEK293細胞)作成100%,算出實施例化合物各濃度中之 尿酸輸送率(% of control uptake ),求出尿酸輸送率於 5〇%所阻礙之實施例化合物濃度(1<:5())。其結果示於表1 [表1] 名稱 構造式 hURATl Ι05〇(μΜ) 4-(1-((4-甲基苯並噻吩-3-基) 甲基)苯並咪唑-2-硫代)丁酸 /-COOH 6.40 厂 COOH 4-( 1 -((4-甲基-1 -氧基苯並噻吩 -3 -基)甲基)苯並咪唑-2-硫代) j 43.8 丁酸 。令 -33- 200916098 由上述實施例(使用人體URAT1發現細胞之尿酸輸 送阻礙試驗)證明,顯示4-(1-( (4_甲基苯並噻吩_3_基 )甲基)苯並咪唑-2-硫代)丁酸及4_(丨_( (4_甲基-^ 氧基苯並噻吩-3-基)甲基)苯並咪唑_2_硫代)丁酸具有 阻礙U R A T 1活性之作用。此係代表* _ (丨_ ( ( 4 _甲基苯 並噻吩-3-基)甲基)苯並咪唑-2-硫代)丁酸及4-(1-( (4-甲基-1-氧基苯並噻吩_3_基)甲基)苯並咪唑_2_硫代 )丁酸具有抑制尿酸之再吸收。 因此’ 4-(1-( (4 -甲基苯並噻吩_3_基)甲基)苯並 咪唑-2 -硫代)丁酸及4 - ( 1 - (( 4 -甲基-1 -氧基苯並噻吩-3-基)甲基)苯並咪唑-2-硫代)丁酸係藉由阻礙URAT1 活性,阻礙腎臟中尿酸之再吸收,顯示促進尿酸之尿中排 泄,降低血中尿酸値。 [實施例3 ] 調製換組之人體m a s t c e 11酵素製劑 換組製劑型人體mast cell酵素製劑係依浦田等之報 告(Journal · of· biogical · chemistry 第 2 6 6 卷、17 17 3 頁(1 9 9 1年))所調製。亦即,由感染含有塗層人體m a s t c e丨】酵素製劑,c D N A的換組 V a c u r o病毒之昆蟲細胞( Th5)培養液上清液藉由肝素瓊脂糖(farmacia)進行精製 。更依村上等之報告(Journal· of· biogical· chemistry 第270卷,2218頁( 1 995年))使人體mast cell酵素製劑 進行活化後’以肝素瓊脂糖進行精製取得活化型人體m a s t cell酵素製劑。 -34- 200916098 [實施例4] 換組人體mast cell酵素製劑之酵素活性阻 礙測定 於含有實施例3取得之1〜5ng之活性型人體mast cell酵素製劑之50μ1之緩衝液A(〇_5〜3.0M NaCl、 5〇mM三鹽酸、pH8.0)中,添加本發明有效成分之含下式 所不化合物之DMSO溶液2μ1後’加入含有〇 5mM 丁二 銳酵一氨基丙酿一組氨酿一脯氨醋一苯基氣基丙驢對硝基 醯替苯胺(Bakem公司)之50μ1緩衝液a,室溫下反應5 分鐘。測定4 0 5 nm之吸光度的經時變化,調整阻礙活性。 其結果’證明於所有被驗化合物中具I c 5 〇 =丨n Μ以上 ,未達1 ΟηΜ之強烈阻礙活性。Three + Tian A found that the vehicle PCDNA3.1 was subjected to the human URAT1 (hURATl) full-length cDNA of the second Crohning, and the human URAT1 gene was copied to the human body by using the ribonucleoprotein method of lipofactamin 2000 -31 - 200916098. Kidney cells (Η EK 2 9 3 cells). At the same time, only the found vector p c D N A 3 . 1 Η Κ Κ 2 9 3 cells (hereinafter referred to as m 〇 c k cells) was also produced. HEK293 cells or mock cells in which the human URAT1 gene was found by geneticin tolerance were selected. The uric acid identified in 14C was delivered to the cells in the same manner as described below. In the indicator, the human URAT 1 gene appeared to function. HEK293 cells and mock were found in human URAT1 using a medium adjusted to pH 7_2±0.1 containing 0.8% NaCM, 0.04% KC1 '0.1% Glucose, 0.034% NaHC03, 0.02% EDTA-Na, 0.12% HEPES, 0.05% Trypsin. The cultured cell layer of the cells was released, and a cell suspension of 4×10 5 cells/mL was prepared using Dulbeccos' modified Eagledium medium (hereinafter referred to as D-MEM medium) containing 10% fetal bovine serum. A human UR ATI of 105/mL/we 11 was prepared. A suspension of HEK293 cells and a suspension of m0Ck cells were seeded in a 24-well cell culture dish, and cultured in d_mEM medium at 37 ° C for 2 days. The uric acid delivery hinders the test. After the medium was suctioned and removed by each well, the cells were replaced with Hanks' Balanced Salt Solution (HBSS), and a pre-incubator was placed at 37 ° C for about 1 minute. After the hb ss was removed by suction, 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazole-2_thio) was added at various concentrations pre-warmed to 37t. Acid or 4-(1-((4-methyl-1-oxybenzothiophen-3-yl)methyl)benzimidazole-2-thio)butyric acid with a radioactive ligand (identified A solution of uric acid··final concentration i 0μΜ ) -32- 200916098 (hereinafter referred to as 1 4 C-uric acid solution) was kept at a constant temperature for 5 minutes at 37 ° C. After the reaction, the μ c _ uric acid solution was removed by suction, and washed with ice-cold HBSS three times. Human URAT1 was found to have ΗΕΚ293 cells and mock cells dissolved in 〇.imol/L NaOH aqueous solution (hereinafter referred to as cell sample), which was taken by well, mixed with cell samples and emulsified scintillator, and the radiation activity was measured with a liquid scintillator counter. The uric acid delivery rate (% of control) in each concentration of the compound of the example compound was calculated by showing the radioactivity of uric acid delivery specific for UR AT 1 (the human URT1 of the compound of the example without addition (DMSO addition) was made to 100%). Uptake), the concentration of the example compound (1 <: 5 ()) which was hindered by the uric acid delivery rate of 5 % was determined. The results are shown in Table 1 [Table 1] Name Structure hURATl Ι05〇(μΜ) 4-(1-((4-Methylbenzothiophen-3-yl)methyl)benzimidazole-2-thio) Butyric acid / -COOH 6.40 plant COOH 4-( 1 -((4-methyl-1 -oxybenzothiophen-3-yl)methyl)benzimidazole-2-thio) j 43.8 butyric acid.令-33- 200916098 It was confirmed by the above example (the uric acid transport inhibition test using human URAT1 cells) that 4-(1-((4-methylbenzothiophene-3-yl)methyl)benzimidazole- 2-thio)butyric acid and 4_(丨_((4-methyl-oxybenzothiophen-3-yl)methyl)benzimidazole_2-thio)butyric acid have hindered URAT 1 activity effect. This represents * _ (丨_(( 4 _methylbenzothiophen-3-yl)methyl)benzimidazole-2-thio)butyric acid and 4-(1-( (4-methyl-1) -oxybenzothiophene-3-yl)methyl)benzimidazole_2_thio)butyric acid inhibits reuptake of uric acid. Therefore '4-(1-(4-methylbenzothiophene-3-yl)methyl)benzimidazole-2-thio)butyric acid and 4-(1-((4-methyl-1)- Oxybenzothiophen-3-yl)methyl)benzimidazole-2-thio)butyric acid inhibits URT1 reabsorption in the kidney by hindering URAT1 activity, showing uric acid excretion and lowering blood Sodium urate. [Example 3] Modification of a human body mastce 11 enzyme preparation and a preparation of a human body mast cell enzyme preparation is a report of Epuda et al. (Journal of of biogical · chemistry, vol. 26, p. 17 17 3 (1 9 9 1 year)) modulated. That is, the supernatant of the insect cell (Th5) culture medium in which the V a c u r o virus was replaced with the coated human body m a s t c e丨 enzyme preparation, c D N A was purified by heparin agarose (farmacia). Further, according to the report of Murakami (Journal of of Biogical Chemistry, Vol. 270, p. 2218 (1995)), the human mast cell enzyme preparation was activated, and purified by heparin agarose to obtain an activated human mast cell enzyme preparation. . -34- 200916098 [Example 4] The enzyme activity of the human body mast cell enzyme preparation was inhibited from measuring 50 μl of the buffer A containing the 1 to 5 ng of the active human mast cell enzyme preparation obtained in Example 3 (〇_5~ 3.0M NaCl, 5 mM mM trihydrochloric acid, pH 8.0), after adding 2 μl of the DMSO solution containing the compound of the present invention, containing the active ingredient of the present invention, 'adding a group of ammonia containing 〇 5 mM Acesulfate-phenyl phenyl hydrazine p-nitroanilide (Bakem) 50 μl buffer a, reacted at room temperature for 5 minutes. The change in absorbance at 40 nm was measured over time to adjust the inhibitory activity. As a result, it was confirmed that I c 5 〇 = 丨n Μ or more in all the tested compounds, and the strong inhibitory activity of less than 1 ΟηΜ was obtained.
[實施例5] 4- C 4 -甲基-1-氧基苯並噻吩-3·基) 丁酸之合成 甲基)苯並咪唑_2-硫代) 1)化合物No.2之合成 -35- 200916098 【化8】 I rOH ac2o i /-〇ac TO -- 〇i[Example 5] Synthesis of 4-C 4 -methyl-1-oxybenzothiophen-3-yl)butyric acid methyl)benzimidazole_2-thio) 1) Synthesis of Compound No. 2 - 35- 200916098 【化8】 I rOH ac2o i /-〇ac TO -- 〇i
vs Pyridine, THF, rt S 1 2 於2L之加狀燒瓶中加入l(9〇g) 、THF(900mL) 、Pyridine (81mL),持續加入冰冷下 Ac20 ( 95.4mL) ,室溫下進行攪拌2 1小時。使T H F進行減壓濃縮,加入 H2 〇 ( 5 OOmL ) ’ 以 AcOEt ( 90〇mLx2)進行萃取。以 0.1N HCl( 500mL) 、H2〇( 500mLx2)、飽和食鹽水( 5 0 0 m L )將有機層洗淨’以M g S Ο 4進行乾燥後,使濾液進 ί了減壓飽去,取得黃色油2 ( 1 2 0.6 2 g )。(收率1 〇 〇 % ) Ή NMR(CDC13) : (5 7.70(d, J = 8.0Hz, 1H), 7.48(s, 1H), 7.24(t, J = 8.0Hz, 1H), 7.15(d, J = 8.0Hz, 1H), 5.43(s, 2H), 2.73(s, 3H), 2.1 l(s, 3H)。 2 )化合物No.3之合成 【化9】Vs Pyridine, THF, rt S 1 2 Add 1 (9 μg), THF (900 mL), Pyridine (81 mL) to a 2 L flask, and continue to add Ac20 (95.4 mL) under ice-cooling. 1 hour. The T H F was concentrated under reduced pressure, and extracted with H.sub.2 (5 OOmL). The organic layer was washed with 0.1 N HCl (500 mL), H 2 〇 (500 mL×2), and saturated brine (500 mL). After drying with M g S Ο 4, the filtrate was poured under reduced pressure. Obtain yellow oil 2 (1 2 0.6 2 g). (Yield 1 〇〇%) Ή NMR (CDC13): (5 7.70 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.24 (t, J = 8.0 Hz, 1H), 7.15 (d , J = 8.0Hz, 1H), 5.43(s, 2H), 2.73(s, 3H), 2.1 l(s, 3H) 2) Synthesis of Compound No. 3 [Chemical 9]
於2 L之燒杯中加入2 ( 5 6 g ) 、A c Ο Η ( 5 0 0 m L ) ’接 著以滴入漏斗以1小時之時間滴入30% H2〇2 ( 1 43mL ) ’ -36- 200916098 室溫下攪拌2 1小時,更於40 °C下攪拌1小時。於室溫加 入 H20 ( 500mL),以 CH2Cl2 ( 500mLx2)進行萃取,以 H20 ( 500mL ) 、20%硫代硫酸鈉水溶液(800mL X 2 )、 Η2 0 ( 5 0 0 m L )進行有機層之洗淨,以M g S Ο 4進行乾燥後 ,使濾液減壓餾去,取得濕潤之白色結晶1 0 0 · 2 g。以矽膠 柱體色譜儀(CH2C12 : MeOH = 20 : 1 )進行精製該粗體, 取得 3 ( 3 2.02g)(收率 53.3%),及 3,( 12.0g)。 !H NMR(CDC 13 ) : (5 7.7 8 (d, J = 7.6Hz, 1H), 7_39(t, J = 7.6Hz, 1H), 7.31(d, J = 7.6Hz, 1H), 7.02(t, J=1.6Hz, 1H), 5_26(ddd, J=1.6,7.6,15.6Hz, 2H), 2.5 6 ( s, 3 H ),2 · 2 0 ( s, 3H)。 3 )化合物No.5之合成 【化1 Ο】 0Cj~S〜^C〇2Me INNaOH 霣 於3 L之3 口燒瓶中以3 0分鐘的時間依序加入4 ( 72g ) 、THF ( 720mL ) 、IN NaOHaq. ( 404mL ),室溫下 進行擾伴3小時_-·冰冷下’加入1 N H C 1 a q · ( 4 0 4 m L ) ' H20 ( 1 400mL),直接攪拌1整晚。濾取析出之結晶,以 H20 ( 200mLx2 )進行洗淨後’於45°c下進行減壓乾燥7.5 小時,取得白色結晶5 ( 64.5 0 g )(收率94.9% )。 ]H NMR(MeOD) : 5 7.4 9 - 7.4 4 (m, 2H), 7.21-7.16(m, 2H), -37- 200916098 3.30(t, J = 7.2Hz, 2H), 2.49(t, J = 7.2Hz, 2H), 2.02(quin, J = 7.2Hz,2H)。 4)化合物Νο·6之合成 【化1 1】Add 2 ( 5 6 g ), A c Ο Η (500 m L ) to a 2 L beaker. Then add 30% H2〇2 (1 43 mL ) to the funnel for 1 hour. - 200916098 Stir at room temperature for 2 hours and at 40 °C for 1 hour. Add H20 (500mL) at room temperature, extract with CH2Cl2 (500mLx2), wash the organic layer with H20 (500mL), 20% aqueous sodium thiosulfate (800mL X 2 ), Η20 (500m) After drying, the mixture was dried over MgSO 4 , and the filtrate was evaporated under reduced pressure to give a white solid crystals of 1 0 0 · 2 g. The crude product was purified by a silica gel column chromatography (CH2C12: MeOH = 20:1) to afford 3 (3 2.02 g) (yield 53.3%) and 3 (12.0 g). !H NMR(CDC 13 ) : (5 7.7 8 (d, J = 7.6Hz, 1H), 7_39(t, J = 7.6Hz, 1H), 7.31(d, J = 7.6Hz, 1H), 7.02(t , J = 1.6 Hz, 1H), 5_26 (ddd, J = 1.6, 7.6, 15.6 Hz, 2H), 2.5 6 (s, 3 H ), 2 · 2 0 (s, 3H). 3) Compound No. 5 Synthesis [Chemical 1 Ο] 0Cj~S~^C〇2Me INNaOH 霣In a 3 L 3-neck flask, add 4 (72g), THF (720mL), IN NaOHaq. ( 404mL ) in 30 minutes. At room temperature, the disturbance was carried out for 3 hours. _-· Under ice cooling, add 1 NHC 1 aq · ( 4 0 4 m L ) 'H20 (1 400 mL) and stir for 1 full night. The precipitated crystals were collected by filtration, washed with H20 (200 mL×2), and then dried under reduced pressure at 45 ° C for 7.5 hours to obtain white crystals 5 ( 64.5 0 g ) (yield 94.9%). ]H NMR(MeOD) : 5 7.4 9 - 7.4 4 (m, 2H), 7.21-7.16 (m, 2H), -37- 200916098 3.30 (t, J = 7.2 Hz, 2H), 2.49 (t, J = 7.2 Hz, 2H), 2.02 (quin, J = 7.2 Hz, 2H). 4) Synthesis of compound Νο·6 [Chemical 1 1]
I 广 OAc 0¾ + Ο:卜〜I wide OAc 03⁄4 + Ο: Bu ~
於1 L之茄型燒瓶中加入3 ( 30g ) 、Pd ( PPh3 ) 4 C 8. 1 5g ) 、THF ( 3 20mL ),於氮氛圍下,室溫攪拌2小時 。2小時後,加入溶解於τ H F ( 2 8 0 m L )之5 ( 3 0 g ),室 溫下攪拌1 7 · 5小時。將反應液進行氟鎂石過濾’去除P d 殘渣,減壓餾去濾液,取得綿狀之結晶7 0.0 g。此粗體溶 於3 0 °C下C H 2 C12 ( 1 8 0 m L )後,恢復至室溫,取得結晶, 經由濾別取得白色結晶(25 .〇g )。將取得之結晶溶於 CH2C12: MeOH = l : 2後,減壓餾去溶媒,取得白色固體6 (2 0 · 0 g )(收率 3 8.2 % )。 1H NMR(CDC13) : <5 7.7 1-7.74(m, 2H),7.44-7.3 60,2H), 7.28-7.16(m, 3H), 6.09(s, 1H), 5.42(s, 2H), 3.54(quin, J = 6.4Hz, 1H), 3.34(quin, J = 6.4Hz, 1H), 2.72(s, 3H), 2.51-2.40(m, 2H), 2.22(sep, J-6.8Hz, 1H), 2.11(sep. J = 6.8Hz, 1 H)。 -38 - 200916098 [產業上可利用性] 本發明藥劑係適用於URAT 1阻礙劑或降低尿酸値用 劑。又’本發明藥劑係適用於痛風、高尿酸血症、痛風關 節炎、痛風結節、尿路結石、腎結石、腎障礙、痛風腎、 心血管疾病、或腦血管疾病等之尿酸相關之疾病的有效治 療、預防之良好的降低尿酸値用劑、或伴隨痛風或高尿酸 血症之心臟病或腎臟病之預防劑或治療劑。 【圖式簡單說明】 [圖1]圖1係代表4-(1-( (4 -甲基苯並噻吩-3-基) 甲基)苯並咪B坐·2-硫代)丁酸投予後之血中尿酸降低率之 曲線圖。 -39-3 (30 g), Pd (PPh3) 4 C 8.15 g), and THF (3 20 mL) were added to a 1 L eggplant type flask, and the mixture was stirred at room temperature for 2 hours under a nitrogen atmosphere. After 2 hours, 5 (30 g) dissolved in τ H F (280 m L) was added and stirred at room temperature for 17.5 hours. The reaction solution was subjected to filtration of fluorite to remove the residue of P d , and the filtrate was evaporated under reduced pressure to give a crystal of crystals of 70.0 g. The crude product was dissolved in CH 2 C12 (1 80 m L) at 30 ° C, and then returned to room temperature to obtain crystals. White crystals (25 g) were obtained by filtration. The crystals obtained were dissolved in CH2C12: MeOH = 1 : 2, and the solvent was evaporated under reduced pressure to afford 6 (2 0 0 g) (yield 3 8.2 %). 1H NMR (CDC13): <5 7.7 1-7.74 (m, 2H), 7.44-7.3 60, 2H), 7.28-7.16 (m, 3H), 6.09 (s, 1H), 5.42 (s, 2H), 3.54 (quin, J = 6.4 Hz, 1H), 3.34 (quin, J = 6.4 Hz, 1H), 2.72 (s, 3H), 2.51-2.40 (m, 2H), 2.22 (sep, J-6.8Hz, 1H) ), 2.11 (sep. J = 6.8Hz, 1 H). -38 - 200916098 [Industrial Applicability] The agent of the present invention is applied to a URAT 1 inhibitor or a urate-reducing agent. Further, the pharmaceutical system of the present invention is applicable to uric acid-related diseases such as gout, hyperuricemia, gout arthritis, gout nodules, urinary calculi, kidney stones, renal disorders, gout kidneys, cardiovascular diseases, or cerebrovascular diseases. A prophylactic or therapeutic agent for reducing uric acid sputum, or a heart or kidney disease associated with gout or hyperuricemia, which is effective for treatment and prevention. [Simple description of the diagram] [Fig. 1] Fig. 1 represents 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzoimin B-sodium 2-thio)butyric acid A graph of the rate of uric acid reduction in the blood after administration. -39-
Claims (1)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007157336 | 2007-06-14 | ||
JP2007259870 | 2007-10-03 | ||
JP2007315718 | 2007-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200916098A true TW200916098A (en) | 2009-04-16 |
Family
ID=40129732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW097122309A TW200916098A (en) | 2007-06-14 | 2008-06-13 | Agent for lowering uric acid level |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW200916098A (en) |
WO (1) | WO2008153129A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107987006A (en) * | 2017-12-20 | 2018-05-04 | 华润赛科药业有限责任公司 | Indoles or azaindole analog derivative, its preparation method and application |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2511065T3 (en) * | 2009-06-17 | 2014-10-22 | Ono Pharmaceutical Co., Ltd. | New compound imidazopyridine |
CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
US9695149B2 (en) | 2013-03-15 | 2017-07-04 | Janssen Pharmaceutica Nv | 1,2,6-substituted benzimidazoles as flap modulators |
WO2014151367A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | 1,2,5-substituted benzimidazoles as flap modulators |
BR112015027303B1 (en) | 2013-05-13 | 2023-04-25 | Jiangsu Hengrui Medicine Co.,Ltd. | CYCLOALKYL ACID DERIVATIVE, METHOD OF PREPARATION OF THE SAME, AND PHARMACEUTICAL APPLICATIONS OF THE SAME |
CN108084153A (en) * | 2017-12-20 | 2018-05-29 | 广东赛烽医药科技有限公司 | Pyridylthio acetic acid compound, composition and its application |
CN111943957B (en) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | Quinoline formamide compound and preparation method and application thereof |
CN110885318B (en) * | 2019-11-28 | 2022-12-23 | 苏州大学 | Benzoxazole derivative and preparation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2550959C3 (en) * | 1975-11-13 | 1980-12-04 | Hoechst Ag, 6000 Frankfurt | Tetrazolyl-imidazoles and tetrazolyl-benzimidazoles, processes for their preparation and pharmaceuticals containing them |
FR2658511B1 (en) * | 1990-02-16 | 1992-06-19 | Union Pharma Scient Appl | NOVEL BENZIMIDAZOLE AND AZABENZIMIDAZOLE DERIVATIVES, THROMBOXANE RECEPTOR ANTAGONISTS; THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5021448A (en) * | 1990-02-22 | 1991-06-04 | Ciba-Geigy Corporation | Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist |
EE04904B1 (en) * | 1998-07-15 | 2007-10-15 | Teijin Limited | Thiobenzimidazole derivatives and a pharmaceutical composition |
DK1249450T3 (en) * | 2000-01-17 | 2008-02-11 | Teijin Pharma Ltd | Benzimidazole derivatives as human chymase inhibitors |
AU2001264729A1 (en) * | 2000-05-22 | 2001-12-03 | Nitromed, Inc. | Thromboxane inhibitors, compositions and methods of use related applications |
UA95788C2 (en) * | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
EP2074121B1 (en) * | 2006-10-06 | 2016-11-30 | Boehringer Ingelheim International GmbH | Chymase inhibitors |
-
2008
- 2008-06-13 WO PCT/JP2008/060845 patent/WO2008153129A1/en active Application Filing
- 2008-06-13 TW TW097122309A patent/TW200916098A/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107987006A (en) * | 2017-12-20 | 2018-05-04 | 华润赛科药业有限责任公司 | Indoles or azaindole analog derivative, its preparation method and application |
CN107987006B (en) * | 2017-12-20 | 2021-06-01 | 华润赛科药业有限责任公司 | Indole or azaindole derivatives, preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2008153129A1 (en) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200916098A (en) | Agent for lowering uric acid level | |
TWI471325B (en) | Indole (Indolizine) derivatives and their pharmaceutical use | |
AU2014267974B2 (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
JP5922116B2 (en) | Compounds that produce general anti-inflammatory responses that act at multiple prostaglandin receptors | |
TW200406412A (en) | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | |
NO324049B1 (en) | Benzimidazole derivatives, their use in the manufacture of therapeutic agents for the treatment of diseases and pharmaceutical compositions comprising such | |
WO2017107864A1 (en) | Benzimidazole derivatives, preparation method therefor, and applications thereof | |
JP2011042655A (en) | Compound inhibiting in vivo phosphorus transport and medicine containing the same | |
TW200803852A (en) | Inhibitors of histone deacetylase for the treatment of disease | |
CN111511736B (en) | Nitrogen-containing 6-membered ring compound | |
CN104053439A (en) | Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid | |
CN105980379A (en) | Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof | |
WO2017036318A1 (en) | 1,2,3,4-tetrahydroisoquinoline derivative, preparation method therefor and application thereof | |
TWI555744B (en) | Novel EP4 agonists | |
WO2021249337A1 (en) | Dimethylsulfoximine derivative | |
US10017521B2 (en) | Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | |
JP6298172B2 (en) | GPR142 agonist compound | |
WO2022127904A1 (en) | Pharmaceutically acceptable salt of indazole derivative, and crystalline form and preparation method therefor | |
CN109843283B (en) | Urea derivatives | |
JP5694959B2 (en) | 3-Benzofuranyl-indol-2-one derivatives substituted in the 3-position, their preparation and therapeutic use | |
US20240025845A1 (en) | Metastasis-inhibiting composition of novel methylsulfonamide derivative compound | |
CN103880797B (en) | Benzofuran compounds and medicinal use thereof | |
RU2667486C2 (en) | Alkynyl indazole derivative and use thereof | |
CN107987042B (en) | A kind of acetylpiperazine compound containing benzofuryl group and its application in medicine | |
TW200827343A (en) | Novel phenylacetic acid derivative |